ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ЛЕЧЕНИЯ COVID-19-АССОЦИИРОВАННЫХ ПНЕВМОНИЙ У ПАЦИЕНТОВ ГРОДНЕНСКОЙ ОБЛАСТИ

Συγγραφείς: С. Н. Демидик, С. Б. Вольф, О. Н. Могилевец, Е. Н. Алексо, С. А. Ляликов, И. А. Курстак

Πηγή: Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 21, Iss 3, Pp 231-236 (2023)

Θεματικοί όροι: новая коронавирусная инфекция, интерстициальное поражение легких, пневмония, компьютерная томография, Medicine

Περιγραφή αρχείου: electronic resource

Relation: http://journal-grsmu.by/index.php/ojs/article/view/3048; https://doaj.org/toc/2221-8785; https://doaj.org/toc/2413-0109

Σύνδεσμος πρόσβασης: https://doaj.org/article/0818e39594564f33819cff2247287af0

Features of systemic autoimmune disease associated with anti-Ku antibodies (descriptions of two clinical cases) ; Особенности течения системного аутоиммунного заболевания, ассоциированного с антителами к Ku-антигену (описание двух клинических случаев)

Συγγραφείς: Anna V. Torgashina, Anna N. Khelkovskaya-Sergeeva, Askat O. Abdykerimov, Alsu R. Khalmetova, А. В. Торгашина, А. Н. Хелковская-Сергеева, А. О. Абдыкеримов, А. Р. Хальметова

Συνεισφορές: Исследование выполнено в рамках выполнения государственного задания по теме FURS-2022-003 (номер государ- ственного задания 1021051402790-6) «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний».

Πηγή: Rheumatology Science and Practice; Vol 62, No 4 (2024); 435–440 ; Научно-практическая ревматология; Vol 62, No 4 (2024); 435–440 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: интерстициальное поражение легких, overlap syndrome, scleroderma, Sjögren’s syndrome, myositis, interstitial lung disease, перекрестный синдром, системная склеродермия, синдром Шегрена, миозит

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3613/2395; Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:859-890.; Casal-Dominguez M, Pinal-Fernandez I, Derfoul A, Graf R, Michelle H, Albayda J, et al. The phenotype of myositis patients with anti-Ku autoantibodies. Semin Arthritis Rheum. 2021;51(4):728-734. doi:10.1016/j.semarthrit.2021.04.012; Belizna C, Henrion D, Beucher A, Lavigne C, Ghaali A, Lévesque H. Anti-Ku antibodies: Clinical, genetic and diagnostic insights. Autoimmun Rev. 2010;9(10):691-694. doi:10.1016/j.autrev.2010.05.020; Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis – scleroderma overlap. J Clin Invest. 1981;68:611-620.; Mimori T. Clinical significance of anti-Ku autoantibodies – A serologic marker of overlap syndrome? Intern Med. 2002;41(12): 1096-1098. doi:10.2169/internalmedicine.41.1096; Cooley HM, Melny BJ, Gleeson R, Greco T, Kay TW. Clinical and serological associations of anti-Ku antibody. J Rheumatol. 1999;26:563-567.; Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Tonello M, Bendo R, et al. Gli anticorpi miosite specifici e miosite associati nelle miopatie infiammatorie idiopatiche: Studio sierologico di 46 pazienti [Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: A serologic study of 46 patients]. Reumatismo. 2005;57(1):22-28. (In Italian). doi:10.4081/reumatismo.2005.22; Selva -O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum. 2006;55(5):791-798. doi:10.1002/art.22237; Yaneva M, Arnett FC. Antibodies against Ku protein in sera from patients with autoimmune diseases. Clin Exp Immunol. 1989;76:366-372.; McClain MT, Ramsland PA, Kaufman KM, James JA. Anti-Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J Immunol. 2002;168(4):2054-2062. doi:10.4049/jimmunol.168.4.2054; Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: Insights into clinical features and outcomes. Arthritis Res Ther. 2007;9(4):R78. doi:10.1186/ar2276; Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996;39(9):1507-1518. doi:10.1002/art.1780390910; Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum. 1992;35(4):449-456. doi:10.1002/art.1780350415; Wang J, Satoh M, Kabir F, Shaw M, Domingo MA, Mansoor R, et al. Increased prevalence of autoantibodies to Ku antigen in African American versus white patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2367-2370. doi:10.1002/1529-0131(200110)44:103.0.co;2-i; Villalta D, Tozzoli R, Tonutti E, Bizzaro N. The laboratory approach to the diagnosis of autoimmune diseases: Is it time to change? Autoimmun Rev. 2007;6(6):359-365. doi:10.1016/j.autrev.2007.01.009; Franceschini F, Cavazzana I, Generali D, Quinzanini M, Viardi L, Ghirardello A, et al. Anti-Ku antibodies in connective tissue diseases: Clinical and serological evaluation of 14 patients. J Rheumatol. 2002;29:1393-1397.; Spielmann L, Nespola B, Séverac F, Andres E, Kessler R, Guffroy A, et al. Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Ann Rheum Dis. 2019;78(8):1101-1106. doi:10.1136/annrheumdis-2018-214439; Lieber MR, Ma Y, Pannicke U, Schwarz K. The mechanism of vertebrate nonhomologous DNA end joining and its role in V(D)J recombination. DNA Repair. 2004;3:817-826.; Schild-Poulter C, Su A, Shih A, Kelly OP, Fritzler MJ, Goldstein R, et al. Association of autoantibodies with Ku and DNA repair proteins in connective tissue diseases. Rheumatology (Oxford). 2008;47(2):165-171. doi:10.1093/rheumatology/kem338; Rigolet A, Musset L, Dubourg O, Maisonobe T, Grenier P, Charuel JL, et al. Inflammatory myopathies with anti-Ku antibodies: A prognosis dependent on associated lung disease. Medicine (Baltimore). 2012;91(2):95-102. doi:10.1097/MD.0b013e31824d9cec; Kishi T, Miyamae T, Morimoto R, Ishiguro N, Hamaguchi Y, Fujimoto M, et al. Childhood-onset anti-Ku antibody-positive generalized morphea with polymyositis: A Japanese case study. Pediatr Dermatol. 201532(5):e224-e225. doi:10.1111/pde.12644; Meek K, Gupta S, Ramsden DA, Lees-Miller SP. The DNAdependent protein kinase: The director at the end. Immunol Rev. 2004;200:132-141. doi:10.1111/j.0105-2896.2004.00162.x; Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-347.; van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall L, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi:10.1136/annrheumdis-2013-204424; Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/ European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35-45. doi:10.1002/art.39859; Fredi M, Cavazzana I, Quinzanini M, Taraborelli M, Cartella S, Tincani A, et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus. 2014;23(7):672-677. doi:10.1177/0961203314524850; Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5(2):80-93. doi:10.1186/ar628; Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airò P, Cattaneo R, et al. Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus. 2008;17(8):727-732. doi:10.1177/0961203308089442; Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, et al. Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: Clinical associations. Medicine (Baltimore). 2016;95(35):e4713. doi:10.1097/MD.0000000000004713

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3613
https://doi.org/10.47360/1995-4484-2024-435-440

Алгоритмы лечения системной склеродермии с преимущественным поражением сердца, развитием легочной артериальной гипертензии и интерстициальным поражением легких согласно современным рекомендациям

Συγγραφείς: Golovach, I.Yu., Yehudina, Ye.D.

Πηγή: HYPERTENSION; № 1.63 (2019); 44-52
АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ; № 1.63 (2019); 44-52
АРТЕРІАЛЬНА ГІПЕРТЕНЗІЯ; № 1.63 (2019); 44-52

Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, системная склеродермия, поражение сердца, миокардит, перикардит, интерстициальное поражение легких, легочная артериальная гипертензия, алгоритмы лечения, системна склеродермія, ураження серця, міокардит, перикардит, інтерстиціальне ураження легень, легенева артеріальна гіпертензія, алгоритми лікування, systemic sclerosis, heart lesion, myocarditis, pericarditis, interstitial lung disease, pulmonary arterial hypertension, treatment algorithms, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://hypertension.zaslavsky.com.ua/article/download/162954/165327
http://hypertension.zaslavsky.com.ua/article/view/162954
http://hypertension.zaslavsky.com.ua/article/download/162954/165327
http://hypertension.zaslavsky.com.ua/article/view/162954

Ovarian reserve in patients with systemic sclerosis ; Овариальный резерв при системной склеродермии

Συγγραφείς: R. G. Goloeva, L. P. Ananyeva, Z. S. Alekberova, S. I. Glukhova, M. V. Cherkasova, L. A. Garzanova, O. A. Koneva, T. M. Reshetnyak, Р. Г. Голоева, Л. П. Ананьева, З. С. Алекберова, С. И. Глухова, М. В. Черкасова, Л. А. Гарзанова, О. А. Конева, Т. М. Решетняк

Συνεισφορές: Работа выполнена за счет средств бюджетного финансирования на выполнение государственного задания по фундаментальной научной теме № 12204004000-7 «FURS-2022-003».

Πηγή: Rheumatology Science and Practice; Vol 61, No 3 (2023); 349–355 ; Научно-практическая ревматология; Vol 61, No 3 (2023); 349–355 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: интерстициальное поражение легких, ovarian reserve, anti-Müllerian hormone, premature ovarian insufficiency, interstitial lung damage, овариальный резерв, антимюллеров гормон, преждевременная недостаточность яичников

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3362/2290; Denton C, Khanna D. Systemic sclerosis. Lancet. 2017;390 (10103):1685-1699. doi:10.1016/S0140-6736(17)30933-9; Овсянникова ОБ, Ананьева ЛП, Конева ОА, Гарзанова ЛА, Десинова ОВ, Шаяхметова РУ, и др. Трансплантация аутологичных гемопоэтических стволовых клеток в лечении системной склеродермии. Часть 2. Безопасность и осложнения. Современная ревматология. 2021;15(1):66-72. doi:10.14412/1996-7012-2021-1-66-72; Jutiviboonsuk A, Salang L, Eamudomkarn N, Mahakkanukrauh A, Suwannaroj S, Foocharoen C. Prevalence and clinical associations with premature ovarian insufficiency, early menopause, and low ovarian reserve in systemic sclerosis. Clin Rheumatol. 2021;40(6):2267-2275. doi:10.1007/s10067-020-05522-5; Steen V, Medsger T, Fertility and pregnancy outcome in women with systemic sclerosis. Arthritis Rheum. 1999;42(4):763-768. doi:10.1002/1529-0131(199904)42:43.0.CO;2-V; Bhadauria S, Moser DK, Clements PJ, Singh RR, Lachenbruch PA, Pitkin RM, et al. Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am J Obstet Gynecol. 1995;172(2 Pt 1):580-587. doi:10.1016/0002-9378(95)90576-6; Nigam A, Prakash A, Sharma S, Kumar N. Premature ovarian failure – an unusual manifestation of systemic sclerosis. J Hum Reprod Sci. 2017;10(1):58-60. doi:10.4103/jhrs.JHRS_77_16; Kauffman R, Castracane V. Premature ovarian failure associated with autoimmune polyglandular syndrome: Pathophysiological mechanisms and future fertility. J Womens Health (Larchmt). 2003;12(5):513-520. doi:10.1089/154099903766651649; Kalantaridou S, Davis S, Nelson L. Premature ovarian failure. Endocrin Metab Clin. 1998;27:989-1006. doi:10.1016/s0889-8529(05)70051-7; Anasti J. Premature ovarian failure: an update. Fertil Steril. 1998;70:1-15. doi:10.1016/s0015-0282(98)00099-5; Coulam C, Ryan R. Prevalence of circulating antibodies directed toward ovaries among women with premature ovarian failure. Am J Reprod Immunol Microbiol. 1985;9:23-24. doi:10.1111/j.1600-0897.1985.tb00336.x; Forges T, Monnier-Barbarino P, Faure G, Bene M. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update. 2004;10:163-175. doi:10.1093/humupd/dmh014; Gasparin AA, Chakr RM, Brenol CV, Palominos PE, Xavier RM, Souza L, et al. Hormônio anti-Mülleriano como preditor de reserva ovariana em pacientes lúpicas: Uma revisão [Anti-Müllerian hormone levels as a predictor of ovarian reserve in systemic lupus erythematosus patients: A review]. Rev Bras Reumatol. 2015;55(4): 363-367 (In Portuguese). doi:10.1016/j.rbr.2014.05.008; Lee MM, Donahoe PK. Müllerian inhibiting substance: A gonadal hormone with multiple functions. Endocr Rev. 1993;14(2):152-164. doi:10.1210/edrv-14-2-152; La Marca A, Stabile G, Artenisio A, Volpe A. Serum anti-Müllerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21(12):3103-3107. doi:10.1093/humrep/del291; Visser J, De Jong F, Laven J, Themmen A. Anti-Müllerian hormone: A new marker for ovarian function. Reproduction. 2006; 131(1):1-9. doi:10.1530/rep.1.00529; Fréour T, Mirallié S, Bach-Ngohou K, Denis M, Barrière P, Masson D. Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: Comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta. 2007;375(1-2):162-164. doi:10.1016/j.cca.2006.06.013; Broekmans F, Kwee J, Hendriks D. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685-718. doi:10.1093/humupd/dml034; van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumato logy/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747. doi:10.1002/art.38098; Henes M, Froeschlin J, Taran FA, Brucker S, Rall KK, Xenitidis T, et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: Impact of rheumatoid arthritis, Behçet’s disease and spondyloarthritis on anti-Müllerian hormone levels. Rheumatology (Oxford). 2015;54(9):1709-1712. doi:10.1093/rheumatology/kev124; Власова ГА, Перминова СГ, Кошелева НМ. Подходы к реализации репродуктивной функции у женщин с системной красной волчанкой и антифосфолипидным синдромом. Гинекология. 2021;23(2):167-172. doi:10.26442/20795696.2021.2.200739; Yalçın Bahat P, Kadiroğulları P, Topbas Selcuki NF, Yücel B, Çakmak K, Üreyen Özdemir E. Ovarian reserve in patients with ankylosing spondylitis. Arch Gynecol Obstet. 2021;303(1):189-193. doi:10.1007/s00404-020-05824-8; Brouwer J, Laven J, Hazes J, Schipper I, Dolhain R. Levels of serum anti-Mullerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65:1534-1538. doi:10.1002/acr.22013; Алекберова ЗС, Егорова ОН, Голоева РГ, Черкасова МВ. Антиммюллеров гормон при системной красной волчанке. Современная ревматология. 2021;15(1):105-110. doi:10.14412/1996-7012-2021-1-105-110; Luo W, Mao P, Zhang L, Chen X, Yang Z. Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: A meta-analysis. Ann Palliat Med. 2020;9(2):207-215. doi:10.21037/apm.2020.02.11; Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev. 1997;18(1):107-134. doi:10.1210/edrv.18.1.0291; Vural B, Caliskan E, Doger E, Ercin C. Uterine prolapse in a young nulligravida with scleroderma and premature ovarian failure. Int Urogynecol J Pelvic Floor Dysfunct. 2003;16:415-417. doi:10.1007/s00192-004-1269-y; Esteves SC, Roque M, Bedoschi GM, Conforti A, Humaidan P, Alviggi C. Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON criteria-the why. Front Endocrinol (Lausanne). 2018;17(9):461. doi:10.3389/fendo.2018.00461; Сигидин ЯА, Гусева НГ, Иванова ММ. Диффузные болезни соединительной ткани. Руководство для врачей. М.:Медицина;2004.; Mok C, Lau C, Wong R. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41:831-837. doi:10.1002/1529-0131 (199805)41:53.0.CO;2-1; Laskari K, Zintzaras E, Tzioufas AG. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil. Clin Exp Rheumatol. 2010;28(1):83-86.; Ioannidis J, Katsifis G, Tzioufas A, Moutsopoulos H. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol. 2002;29(10):2129-2135.; D’Angelo S, Cuomo G, Paone C, Colutta E, La Montagna G, Valentini G. Low-dose intravenous cyclophosphamide in systemic sclerosis: A preliminary safety study. Clin Rheumatol. 2003;22(6):393-396. doi:10.1007/s10067-003-0756-8; Vinet É, Bernatsky S, Hudson M, Pineau CA, Baron M; Canadian Scleroderma Research Group. Effect of menopause on the modified Rodnan skin score in systemic sclerosis. Arthritis Res Ther. 2014;16(3):R130. doi:10.1186/ar4587

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3362
https://doi.org/10.47360/1995-4484-2023-349-355

Rituximab in the treatment of systemic sclerosis. Literature review ; Ритуксимаб в лечении системной склеродермии

Συγγραφείς: L. A. Garzanova, Л. А. Гарзанова

Συνεισφορές: Работа выполнена за счет средств бюджетного фи- нансирования на выполнение государственного задания по теме FURS-2022-003 (номер государственного задания 1021051402790-6)

Πηγή: Rheumatology Science and Practice; Vol 61, No 4 (2023); 466-474 ; Научно-практическая ревматология; Vol 61, No 4 (2023); 466-474 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: нежелательные явления, rituximab, interstitial lung disease, skin fibrosis, adverse events, ритуксимаб, интерстициальное поражение легких, фиброз кожи

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3401/2306; Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017; 390(10103):1685-1699. doi:10.1016/S0140-6736(17)30933-9; Kowalska-Kepczynska A. Systemic scleroderma – definition, clinical picture and laboratory diagnostics. J Clin Med. 2022;11:2299. doi:10.3390/jcm11092299; Hughes M, Pauling J, Armstrong-James L, Denton CP, Galdas PM, Flurey C. Gender-related differences in systemic sclerosis. Autoimmun Rev. 2020;19(4):102494. doi:10.1016/j.autrev.2020.102494; Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema EV, Holmqvist M. Incidence and prevalence of systemic sclerosis globally: A comprehensive systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(7):3121-3133. doi:10.1093/rheumatology/keab190; Roofeh D, Khanna D. Management of systemic sclerosis: The first five years. Curr Opin Rheumatol. 2020;32(3):228-237. doi:10.1097/BOR.0000000000000711; Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies. Rheumatology. 2020;51:1017-1026. doi:10.1093/rheumatology/ker269; Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: A retrospective cohort study. QJM. 2010;103(2):109-115. doi:10.1093/qjmed/hcp174; Rubio-Rivas M, Royo C, Simeón-Aznar CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):208-219. doi:10.1016/j.semarthrit.2014.05.010; Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019;20(1):13. doi:10.1186/s12931-019-0980-7; Crunkhorn S. Epigenetic mechanism of systemic sclerosis. Nat Rev Drug Discov. 2019;18(8):584. doi:10.1038/d41573-019-00112-w; Allanore Y. Pathophysiology of systemic sclerosis. Med Sci (Paris). 2016;32(2):183-191. doi:10.1051/medsci/20163202012; Brown M, O’Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019;195(3):310-321. doi:10.1111/cei.13238; Van den Hoogen F, Khanna D, Fransen J. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative: ACR/EULAR Classification Criteria for SSc. Arthritis Rheum. 2013;65:2737-2747. doi:10.1002/art.38098; Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340-354. doi:10.1016/j.autrev.2012.05.011; Stern EP, Denton CP. The pathogenesis of systemic sclerosis. Rheum Dis Clin North Am. 2015;41(3):367-382. doi:10.1016/j.rdc.2015.04.002; Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018;195:76-82. doi:10.1016/j.imlet.2018.01.002; Thoreau B, Chaigne B, Mouthon L. Role of B-cell in the pathogenesis of systemic sclerosis. Front Immunol. 2022;13:933468. doi:10.3389/fimmu.2022.933468; Sanges S, Guerrier T, Launay D, Lefèvre G, Labalette M, Forestier A, et al. Role of B cells in the pathogenesis of systemic sclerosis. Rev Med Interne. 2017;38(2):113-124. doi:10.1016/j.revmed.2016.02.016; Насонов ЕЛ (ред.). Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. М.:ИМА-ПРЕСС;2012. [Nasonov EL (ed.). Anti-B-cell therapy in rheumatology: Focus on rituximab. Moscow:IMA-PRESS;2012 (In Russ.)].; Насонов ЕЛ, Зонова ЕВ, Иванова ОН, Князева ЛА, Мазуров ВИ, Самигуллина Р.Р., и др. Результаты сравнительного клинического исследования III фазы препаратов ритуксимаба (Ацеллбия® и Мабтера®) при ревматоидном артрите (исследование BIORA). Научно-практическая ревматология. 2016;54(5):510-519. [Nasonov EL, Zonova EV, Ivanova ON, Knyazeva LA, Mazurov VI, Samigullina RR, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and Mabthera®) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice 2016;54(5):510-519 (In Russ.)] doi:10.14412/1995-4484-2016-510-519; Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52-57. doi:10.3899/jrheum.120778; Thiebaut M, Launay D, Rivière S, Mahévas T, Bellakhal S, Hachulla E, et al. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev. 2018;17(6):582-587. doi:10.1016/j.autrev.2017.12.010; Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46(5):625-631. doi:10.1016/j.semarthrit.2016.10.003; Ананьева ЛП, Денисова ОВ, Конева ОА, Старовойтова МН, Юткина НН, Волков АВ, и др. Лечение ритуксимабом интерстициального поражения легких при системной склеродермии. Научно-практическая ревматология. 2013;51(5):514-523. [Ananieva LP, Desinova OV, Koneva OA, Starovoitova MN, Yutkina NN, Volkov AV, et al. Rituximab treatment for interstitial lung injury in scleroderma systematica. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2013;51(5):514-523 (In Russ.)]. doi:10.14412/1995-4484-2013-1542; Ананьева ЛП, Конева ОА, Десинова ОВ, Гарзанова ЛА, Глухова СИ, Старовойтова МН, и др. Влияние ритуксимаба на проявления активности и легочную функцию у больных системной склеродермией: оценка после года наблюдения. Научнопрактическая ревматология. 2019;57(3):265-273. [Ananyeva LP, Koneva OA, Desinova OV, Garzanova LA, Glukhova SI, Starovoitova MN, et al. Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: Oneyear follow-up evaluation. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice . 2019;57(3):265-273 (In Russ.)]. doi:10.14412/1995-4484-2019-265-273; Ананьева ЛП. Современная терапия интерстициальных пневмоний, ассоциированных с системной склеродермией. Научно-практическая ревматология. 2020;58(5):520-531. [Ananieva LP. Current therapy of interstitial pneumonia associated with systemic scleroderma. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice . 2020;58(5):520-531 (In Russ.)]. doi:10.47360/1995-4484-2020-520-531; Ананьева ЛП, Гарзанова ЛА, Десинова ОВ, Конева ОА, Старовойтова МН, Овсянникова ОБ, и др. Оценка краткосрочной динамики общего числа В-лимфоцитов на фоне лечения ритуксимабом больных системной склеродермией. Научно-практическая ревматология. 2020;58(4):395-400. [Ananieva LP, Garzanova LA, Desinova OV, Koneva OA, Starovoytova MN, Ovsyannikova OB, et al. Short-term absolute B-cell counts monitoring in systemic sclerosis patients treated with rituximab. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice . 2020;58(4):395-400 (In Russ)]. doi:10.47360/1995-4484-2020-395-400; Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al.; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study. Ann Rheum Dis. 2019;78(7):979-987. doi:10.1136/annrheumdis-2018-214816; Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al.; EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-1194. doi:10.1136/annrheumdis-2013-204522; Ананьева ЛП, Соловьев СК, Бекетова ТВ, Васильев ВИ, Антелава ОА, Александрова ЕН, и др. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495-506. [Ananieva LP, Soloviyov SK, Beketova TV, Vasiliev VI, Antelava OA, Aleksandrova EN, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: Efficacy and tolerability in 229 patients. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(5):495-506 (In Russ.)]. doi:10.14412/1995-4484-2014-495-506; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. [Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.)]. doi:10.14412/1995-4484-2019-3-40; Fernández-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70(11):1820-1828. doi:10.1002/art.40560; Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017. [Nasonov EL (ed.). Rheumatology. Russian clinical recommendations. Moscow:GEOTAR-Media;2017 (In Russ.)].; Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: Evidence-based European consensus statements. Lancet Rheumatol. 2020;2:71-83. doi:10.1016/S2665-9913(19)30144-4; Khanna D, Lescoat A, Roofeh D, Bernstein EJ, Kazerooni EA, Roth MD, et al. Systemic sclerosis-associated interstitial lung disease: How to incorporate two food and drug administrationapproved therapies in clinical practice. Arthritis Rheumatol. 2022;74(1):13-27. doi:10.1002/art.41933; Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428-436. doi:10.1016/j.semarthrit. 2014.09.002; Lepri G, Avouac J, Airò P, Anguita Santos F, Bellando-Randone S, Blagojevic J, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016; 34(Suppl 100):181-185.; Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57:2106-2113. doi:10.1093/rheumatology/key213; Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, et al. Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: A multicenter, double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2021;204(2):209-221. doi:10.1164/rccm.202009-3481OC; Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): A double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):489-497. doi:10.1016/S2665-9913(21)00107-7; Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al.; RECITAL Investigators. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): A double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45-54. doi:10.1016/S2213-2600(22)00359-9; Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al.; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. doi:10.1056/NEJMoa1903076; Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al.; focuSSced investigators. Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963-974. doi:10.1016/S2213-2600(20)30318-0; Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630-2640. doi:10.1016/S0140-6736(16)00232-4; Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): Open-label extension of a double-blind, investigators-initiated, randomized, placebo-controlled trial. Lancet Rheumatol. 2022;4(8):546-555. doi:10.1016/S2665-9913(22)00131-X; Ананьева ЛП, Гарзанова ЛА, Конева ОА, Старовойтова МН, Десинова ОВ, Овсянникова ОБ, и др. Динамика аутоантител к топоизомеразе I на фоне лечения ритуксимабом у больных системной склеродермией. Научно-практическая ревматология. 2022;60(1):57-63. [Ananyeva LP, Garzanova LA, Koneva OA, Starovoytova MN, Desinova OV, Ovsyannikova OB, et al. Antitopoisomerase 1 antibody level changes after B сell depletion therapy in systemic sclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022; 60(1):57-63 (In Russ.)]. doi:10.47360/1995-4484-2022-57-63; Koneva O, Ananyeva L, Garzanova L, Desinova O, Ovsyannikova O, Starovoytova M. Rituximab and cyclophosphamide comparison for efficacy and safety in the patients with systemic sclerosis associated with interstitial lung disease. Ann Rheum Dis. 2019;78:169. doi:10.1136/annrheumdis-2019-eular.6816; Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: A systematic review and meta-analysis. Rheumatology. 2021;60:557-567. doi:10.1093/rheumatology/keaa550; Odler B, Hebesberger C, Hoeflechner L, Pregartner G, Gressenberger P, Jud P, et al. Effect of short-interval rituximab and highdose corticosteroids on kidney function in systemic sclerosis: Long-term experience of a single centre. Int J Clin Pract. 2021;75(6):e14069. doi:10.1111/ijcp.14069; Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006; Bournia VK, Tountas C, Protogerou AD, Panopoulos S, Mavrogeni S, Sfikakis PP. Update on assessment and management of primary cardiac involvement in systemic sclerosis. J Scleroderma Relat Disord. 2018;3(1):53-65. doi:10.1177/2397198317747441; Dinser R, Frerix M, Meier FMP, Klingel K, Rolf A. Endocardial and myocardial involvement in systemic sclerosis – is there a relevant inflammatory component? Joint Bone Spine. 2013;80(3):320– 323. doi:10.1016/j.jbspin.2012.10.009; Sharif K, Watad A, Bragazzi NL, Asher E, Abu Much A, Horowitz Y, et al. Anterior ST-elevation myocardial infarction induced by rituximab infusion: A case report and review of the literature. J Clin Pharm Ther. 2017;42(3):356-362. doi:10.1111/jcpt.12522; Braun F, Behrend M. Drugs that act on the immune system: Cytokines and monoclonal antibodies. Side Effects of Drugs Annual. 2008;30:435-451. doi:10.1016/s0378-6080(08)00037-8; Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18(2):317-324. doi:10.1200/JCO.2000.18.2.317; Smith V, Pizzorni C, Riccieri V, Decuman S, Brusselle G, DE Pauw M, et al. Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: An open-label study. J Rheumatol. 2016;43(5):995-886. doi:10.3899/jrheum.151018; Гарзанова ЛА, Ананьева ЛП, Конева ОА, Овсянникова ОБ. Влияние ритуксимаба на поражение сердца при системной склеродермии. Научно-практическая ревматология. 2018;56(6):709-715. [Garzanova LA, Ananyeva LP, Koneva OA, Ovsyannikova OB. Effect of rituximab on heart involvement in systemic sclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice . 2018;56(6):709-715 (In Russ.)]. doi:10.14412/1995-4484-2018-709-715; Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, et al. B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54. doi:10.1186/ar2965; Vital EM, Dass S, Buch MH, Rawstron AC, Emery P. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: A randomised controlled trial. Ann Rheum Dis. 2015;74(6):1195-201. doi:10.1136/annrheumdis-2013-204544; Moradzadeh M, Aghaei M, Mehrbakhsh Z, Arab-Bafrani Z, Abdollahi N. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): Systematic review and metaanalysis. Clin Rheumatol. 2021;40(10):3897-3918. doi:10.1007/s10067-021-05698-4; Xing NS, Fan GZ, Yan F, Liu YP, Zhang R. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int Immunopharmacol. 2021;95:107524. doi:10.1016/j.intimp.2021.107524; St Clair EW. Good and bad memories following rituximab therapy. Arthritis Rheum. 2010;62(1):1-5. doi:10.1002/art.25039; McMahan ZH, Volkmann ER. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opin Pharmacother. 2020;21(16):2041-2056. doi:10.1080/14656566.2020.1793960

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3401
https://doi.org/10.47360/1995-4484-2023-466-474

Аssociation between (rs1024611) -12518A/G CCL2 gene polymorphism and serum level of C-reactive protein with different clinical and serological phenotypes of systemic sclerosis in the Russian cohort of patients

Πηγή: Nauchno-prakticheskii zhurnal «Medicinskaia genetika». :34-39

Θεματικοί όροι: диффузная форма системного склероза, anti-topoisomerase I antibodies (ATA), systemic sclerosis, interstitial lung disease (ILD), интерстициальное поражение легких, аутоантитела к топоизомеразе I, уровни С-реактивного белка, CCL2 gene polymorphism, diffuse form systemic sclerosis (dcSSc), системный склероз, полиморфизм гена CCL2, C-reactive protein levels, 3. Good health

Σύνδεσμος πρόσβασης: https://www.medgen-journal.ru/jour/article/download/699/434

Experience of successful autologous hematopoietic stem cell transplantation in patients with an unfavorable prognosis of systemic scleroderma ; Опыт успешного применения аутологичной трансплантации стволовых гемопоэтических клеток у пациенток с неблагоприятным прогнозом течения диффузной формы системной склеродермии

Συγγραφείς: V. I. Mazurov, A. L. Maslyanskiy, K. E. Zotkina, S. S. Benevolenskaya, D. V. Motorin, A. Yu. Zaritskiy, E. A. Vasilenko, A. A. Vasilenko, A. M. Titova, В. И. Мазуров, А. Л. Маслянский, К. Е. Зоткина, С. С. Беневоленская, Д. В. Моторин, А. Ю. Зарицкий, Е. А. Василенко, А. А. Василенко, А. М. Титова

Πηγή: Rheumatology Science and Practice; Vol 60, No 3 (2022); 381-387 ; Научно-практическая ревматология; Vol 60, No 3 (2022); 381-387 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: интерстициальное поражение легких, systemic scleroderma, interstitial lung disease, системная склеродермия

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3188/2202; Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007;66(7):940-944. doi:10.1136/ard.2006.066068; Goldin JG, Kim GHJ, Tseng CH, Volkmann E, Furst D, Clements P, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc. 2018;15(11):1286-1295. doi:10.1513/AnnalsATS.201802-079OC; Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015;14(11):1072-1078. doi:10.1016/j.autrev.2015.07.008; Zacay G, Levy Y. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. Best Pract Res Clin Rheumatol. 2018;32(4):563-571. doi:10.1016/j.berh.2019.01.011; Авдеев СН, Ананьева ЛП, Жиляев ЕВ, Зонова ЕВ, Клименко АА, Конева ОА, и др. Резолюция Совета экспертов, посвященного теме «Интерстициальные заболевания легких при системной склеродермии» (14 октября 2019 г., Москва). Современная ревматология. 2020;14(1):125-128. doi:10.14412/1996-7012-2020-1-125-128; Новик АА, Богданов АН. Принципы трансплантации костного мозга и стволовых клеток периферической крови. СПб.:Военно-медицинская академия;2001.; European Society for Blood and Marrow Transplantation. Transplant activity survey. URL: https://www.ebmt.org/registry/transplant-activity-survey (Accessed: DD Month 2022).; Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial. Lancet. 2011;378(9790):498-506. doi:10.1016/S0140-6736(11)60982-3; van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al.; EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial. JAMA. 2014;311(24):2490-2498. doi:10.1001/jama.2014.6368; Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al.; SCOT Study Investigators. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35-47. doi:10.1056/nejmoa1703327; Farge D. Stem cell transplantation for systemic sclerosis in Israel: A new star is rising. Isr Med Assoc J. 2020;22(2):116-118.; Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al.; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909; Маслянский АЛ, Мазуров ВИ, Зоткин ЕГ, Иливанова ЕП, Тотолян АА. Анти-В-клеточная терапия аутоиммунных заболеваний. Медицинская иммунология. 2007;9(1):15-34. doi:10.15789/1563-0625-2007-1-15-34

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3188
https://doi.org/10.47360/1995-4484-2022-381-387

Anti-topoisomerase 1 antibody level changes after B сell depletion therapy in systemic sclerosis ; Динамика аутоантител к топоизомеразе I на фоне лечения ритуксимабом у больных системной склеродермией

Συγγραφείς: L. P. Ananyeva, L. A. Garzanova, O. A. Koneva, M. N. Starovoytova, O. V. Desinova, O. B. Ovsyannikova, R. U. Shayakhmetova, M. V. Cherkasova, A. P. Aleksankin, E. L. Nasonov, Л. П. Ананьева, Л. А. Гарзанова, О. А. Конева, М. Н. Старовойтова, О. В. Десинова, О. Б. Овсянникова, Р. У. Шаяхметова, М. В. Черкасова, А. П. Алексанкин, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 60, No 1 (2022); 57–63 ; Научно-практическая ревматология; Vol 60, No 1 (2022); 57–63 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: ритуксимаб, antinuclear antibody, anti-topoisomerase 1 antibody, interstitial lung disease, rituximab, антитела к топоизомеразе I, интерстициальное поражение легких

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3117/2157; Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi:10.1016/S0140-6736(17)30933-9; Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12(3):340-354. doi:10.1016/j.autrev.2012.05.011; Ананьева ЛП, Александрова ЕН. Аутоантитела при системной склеродермии: спектр, клинические ассоциации и прогностическое значение. Научно-практическая ревматология. 2016;54(1):86-99. doi:10.14412/1995-4484-2016-86-99; Bossuyt X, De Langhe E, Borghi MO, Meroni PL. Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nat Rev Rheumatol. 2020;16(12):715-726. doi:10.1038/s41584-020-00522-w; van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747. doi:10.1002/art.38098; Tiniakou E, Crawford J, Darrah E. Insights into origins and specificities of autoantibodies in systemic sclerosis. Curr Opin Rheumatol. 2021;33(6):486-494. doi:10.1097/BOR.0000000000000834; Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010;6(2):112-116. doi:10.1038/nrrheum.2009.238; Nihtyanova SI, Sari A, Harvey JC, Leslie A, Derrett-Smith EC, Fonseca C, et al. Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol. 2020;72(3):465-476. doi:10.1002/art.41153; Kuwana M, Gil-Vila A, Selva-O’Callaghan A. Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2021;13:1759720X211032457. doi:10.1177/1759720X211032457; Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018;195:76-82. doi:10.1016/j.imlet.2018.01.002; Melissaropoulos K, Daoussis D. B cells in systemic sclerosis: From pathophysiology to treatment. Clin Rheumatol. 2021;40(7):2621-2631. doi:10.1007/s10067-021-05665-z; Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies targeting intracellular and extracellular proteins in autoimmunity. Front Immunol. 2021;12:548469. doi:10.3389/fimmu.2021.548469; Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S. Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 2011;63(11):3575-3585. doi:10.1002/art.30539; Mehta H, Goulet PO, Nguyen V, Pérez G, Koenig M, Senécal JL, et al. Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis. Autoimmunity. 2016;49(8):503-513. doi:10.1080/08916934.2016.1230848; Cottrell TR, Askin F, Halushka MK, Casciola-Rosen L, McMahan ZH. Expression of the autoantigen topoisomerase-1 is enriched in the lung tissues of patients with autoimmune interstitial lung disease: A case control study. ACR Open Rheumatol. 2020;2(11):657-661. doi:10.1002/acr2.11191; Fava A, Cimbro R, Wigley FM, Liu QR, Rosen A, Boin F. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res Ther. 2016;18(1):99. doi:10.1186/s13075-016-0993-2; Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum. 2000;43(5):1074-1084. doi:10.1002/1529-0131(200005)43:53.0.CO;2-E; Einhaus J, Pecher AC, Asteriti E, Schmid H, Secker KA, DuerrStoerzer S, et al. Inhibition of effector B cells by ibrutinib in systemic sclerosis. Arthritis Res Ther. 2020;22(1):66. doi:10.1186/s13075-020-02153-8; Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum. 2003;48(5):1363-1373. doi:10.1002/art.10977; Sato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford). 2001;40(10):1135-1140. doi:10.1093/rheumatology/40.10.1135; Henes J, Glaeser L, Kötter I, Vogel W, Kanz L, Klein R. Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. Rheumatology (Oxford). 2017;56(3):451-456. doi:10.1093/rheumatology/kew319; Насонов ЕЛ (ред.). Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. М.:ИМА-ПРЕСС;2012.; Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi:10.1038/s41573-020-00092-2; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. doi:10.14412/1995-4484-2019-3-40; Ананьева ЛП, Денисова ОВ, Конева ОА, Старовойтова МН, Юткина НН, Волков АВ, и др. Лечение ритуксимабом интерстициального поражения легких при системной склеродермии. Научно-практическая ревматология. 2013;51(5):514-523. doi:10.14412/1995-4484-2013-1542; Ананьева ЛП, Конева ОА, Десинова ОВ, Гарзанова ЛА, Глухова СИ, Старовойтова МН, и др. Влияние ритуксимаба на проявления активности и легочную функцию у больных системной склеродермией: оценка после года наблюдения. Научно-практическая ревматология. 2019;57(3):265-273. doi:10.14412/1995-4484-2019-265-273; Moradzadeh M, Aghaei M, Mehrbakhsh Z, Arab-Bafrani Z, Abdollahi N. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): Systematic review and metaanalysis. Clin Rheumatol. 2021;40(10):3897-3918. doi:10.1007/ s10067-021-05698-4; Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: A systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(2):557-567. doi:10.1093/ rheumatology/keaa550; de Figueiredo Caldas MMV, de Azevedo KPM, de França Nunes AC, de Oliveira VH, Pimenta IDSF, de Araújo IDT, et al. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. Adv Rheumatol. 2021;61(1):15. doi:10.1186/s42358-021-00170-y; Moazedi-Fuerst FC, Kielhauser SM, Hermann J, Meilinger M, Demel U, Stradner MH, et al. Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: A promising surveillance marker of therapy? Scand J Rheumatol. 2015;44(6):519-520. doi:10.3109/03009742.2015.1069888; Bonroy C, Smith V, Deschepper E, De Keyser F, Devreese K. Specific antinuclear antibody level changes after B cell depletion therapy in systemic sclerosis are associated with improvement of skin thickening. J Rheumatol. 2016;43(1):247-249. doi:10.3899/jrheum.150105; Ebata S, Yoshizaki A, Fukasawa T, Miura S, Takahashi T, Sumida H, et al. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with antitopoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol. 2019;46(11):1006-1013. doi:10.1111/1346-8138.15079; Fernández-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70(11):1820-1828. doi:10.1002/art.40560; Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60(6):592-598. doi:10.1136/ard.60.6.592; Kahaleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC. A modified scleroderma skin scoring method. Clin Exp Rheumatol. 1986;4(4):367-369.; Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al.; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study. Ann Rheum Dis. 2019;78(7):979-987. doi:10.1136/annrheumdis-2018-214816; Hughes M, Denton CP, Khanna D. Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology (Oxford). 2021;60(2):489-491. doi:10.1093/rheumatology/keaa675; Tang R, Yu J, Shi Y, Zou P, Zeng Z, Tang B, et al. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis. Int Immunopharmacol. 2020;83:106389. doi:10.1016/j.intimp.2020.106389; Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, et al. B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54(11):3612-3622. doi:10.1002/art.22211; Lazarus MN, Turner-Stokes T, Chavele KM, Isenberg DA, Ehrenstein MR. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford). 2012;51(7):1208-1215. doi:10.1093/rheumatology/ker526; Tew GW, Rabbee N, Wolslegel K, Hsieh HJ, Monroe JG, Behrens TW, et al. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19(2):146-157. doi:10.1177/0961203309350752; Цанян МЭ, Торгашина АВ, Александрова ЕН, Соловьев СК, Насонов ЕЛ. Антитела к компоненту С1q комплемента у больных системной красной волчанкой на фоне лечения ритуксимабом. Терапевтический архив. 2013;85(5):53-59.; Cambridge G, Leandro MJ, Lahey LJ, Fairhead T, Robinson WH, Sokolove J. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens. J Autoimmun. 2016;70:22-30. doi:10.1016/j.jaut.2016.03.010; Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol. 2013;173(1):8-17. doi:10.1111/cei.12114; Lindenberg L, Spengler L, Bang H, Dorner T, Maslyanskiy AL, Lapin SV, et al. Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):206. doi:10.1186/s13075-015-0717-z; Cortazar FB, Pendergraft WF 3rd, Wenger J, Owens CT, Laliberte K, Niles JL. Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69(5):1045-1053. doi:10.1002/art.40032; van Dam LS, Dirikgil E, Bredewold EW, Ray A, Bakker JA, van Kooten C, et al. PR3-ANCAs predict relapses in ANCAassociated vasculitis patients after rituximab. Nephrol Dial Transplant. 2021;36(8):1408-1417. doi:10.1093/ndt/gfaa066; Heitz M, Carron PL, Clavarino G, Jouve T, Pinel N, GuebreEgziabher F, et al. Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease. BMC Nephrol. 2018;19(1):241. doi:10.1186/s12882-018-1038-7; Uematsu-Uchida M, Ohira T, Tomita S, Satonaka H, Tojo A, Ishimitsu T. Rituximab in treatment of anti-GBM antibody glomerulonephritis: A case report and literature review. Medicine (Baltimore). 2019;98(44):e17801. doi:10.1097/MD.0000000000017801; Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543-1550. doi:10.1681/ASN.2010111125; Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545-2558. doi:10.1681/ASN.2014070640; Arnold DM, Vrbensky JR, Karim N, Smith JW, Liu Y, Ivetic N, et al. The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia. Br J Haematol. 2017;178(2):302-307. doi:10.1111/bjh.14664; Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood. 2015;125(21):3223-3229. doi:10.1182/blood-2015-01-588392; Yu L, Herold K, Krause-Steinrauf H, McGee PL, Bundy B, Pugliese A, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab selectively suppresses specific islet antibodies. Diabetes. 2011;60(10):2560-2565. doi:10.2337/db11-0674; Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: Pooled data from 10 European registries. Ann Rheum Dis. 2011;70(9):1575-1580. doi:10.1136/ard.2010.148759; Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: A meta-analysis. Ann Rheum Dis. 2013;72(3):329-336. doi:10.1136/annrheumdis-2011-201117; Porcelijn L, Huiskes E, Schipperus M, van der Holt B, de Haas M, Zwaginga JJ; Dutch HOVON 64 Study Group. Lack of detectable platelet autoantibodies is correlated with nonresponsiveness to rituximab treatment in ITP patients. Blood. 2017;129(25):3389-3391. doi:10.1182/blood-2016-11-751719; Wang YM, Yu YF, Liu Y, Liu S, Hou M, Liu XG. The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. Hematology. 2020;25(1):139-144. doi:10.1080/16078454.2020.1740430; Crickx E, Weill JC, Reynaud CA, Mahévas M. Anti-CD20- mediated B-cell depletion in autoimmune diseases: Successes, failures and future perspectives. Kidney Int. 2020;97(5):885-893. doi:10.1016/j.kint.2019.12.025; Boonstra M, Bakker JA, Grummels A, Ninaber MK, Ajmone Marsan N, Wortel CM, et al. Association of antitopoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis. Arthritis Rheumatol. 2020;72(11):1897-1904. doi:10.1002/art.41403; Simon D, Balogh P, Erdő-Bonyár S, Böröcz K, Minier T, Czirják L, et al. Increased frequency of activated switched memory B cells and its association with the presence of pulmonary fibrosis in diffuse cutaneous systemic sclerosis patients. Front Immunol. 2021;12:686483. doi:10.3389/fimmu.2021.686483; Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15(Suppl 1):S3. doi:10.1186/ar3908; Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009;60(12):3563-3571. doi:10.1002/art.24998. PMID: 19950291; Eggleton P, Bremer E, Tarr JM, de Bruyn M, Helfrich W, Kendall A, et al. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res Ther. 2011;13(6):R208. doi:10.1186/ar3541; van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011;63(6):1507-1516. doi:10.1002/art.30314; Kuwana M, Medsger TA Jr, Wright TM. Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells. J Immunol. 2000;164(12):6138-6146. doi:10.4049/jimmunol.164.12.6138; Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006;169(3):954-966. doi:10.2353/ajpath.2006.060205; Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54. doi:10.1186/ar2965; She YX, Yu QY, Tang XX. Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov. 2021;7(1):52. doi:10.1038/s41420-021-00437-9; Ананьева ЛП. Перспективы применения тоцилизумаба при системной склеродермии. Научно-практическая ревматология. 2015;53(6):632-640. doi:10.14412/1995-4484-2015-632-640; Shima Y. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. Mod Rheumatol. 2019;29(2):294-301. doi:10.1080/14397595.2018.1559909

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3117
https://doi.org/10.47360/1995-4484-2022-57-63

Pulmonary Involvement at Connective Tissue Systemic Diseases in Children ; Поражение легких при системных заболеваниях соединительной ткани у детей

Συγγραφείς: Maria I. Kaleda, Svetlana O. Salugina, Evgeniy S. Fedorov, Lidia P. Ananyeva, М. И. Каледа, С. О. Салугина, Е. С. Фёдоров, Л. П. Ананьева

Συνεισφορές: Not specified, Не указан

Πηγή: Current Pediatrics; Том 20, № 2 (2021); 134-143 ; Вопросы современной педиатрии; Том 20, № 2 (2021); 134-143 ; 1682-5535 ; 1682-5527

Θεματικοί όροι: легочная артериальная гипертензия, juvenile dermatomyositis, juvenile systemic lupus erythematosus, Sjogren's syndrome in children, interstitial lung disease, pulmonary arterial hypertension, ювенильный дерматомиозит, системная красная волчанка с ювенильным началом, синдром Шегрена у детей, интерстициальное поражение легких

Περιγραφή αρχείου: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/2596/1040; Ревматология. Российские клинические рекомендации / под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа; 2017.; Ha YJ, Lee YJ, Kang EH. Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment. Biomed Res Int. 2018;2018:6930297. doi:10.1155/2018/6930297; Textbook of Pediatric Rheumatology. Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, eds. Philadelphia, PA: Elsiever Saunders; 2016.; Shiff NJ, Lix LM, Joseph L, et al. The prevalence of systemic autoimmune rheumatic diseases in Canadian pediatric populations: administrative database estimates. Rheumatol Int. 2015;35(3): 569-573. doi:10.1007/s00296-014-3136-6; Denardo BA, Tucker LB, Miller LC, et al. Demography of a regional pediatric rheumatology patient population. Affiliated Children's Arthritis Centers of New England. J Rheumatol. 1994;21(8):1553-1561.; Patra PK, Kumar M. Clinico-epidemiological profile of pediatric rheumatology disorders in Eastern India. J Nat Sci Biol Med. 2018; 9(1):19-22. doi:10.4103/jnsbm.JNSBM_80_17; Rosenberg AM. Longitudinal analysis of a pediatric rheumatology clinic population. J Rheumatol. 2005;32(10):1992-2001.; Dell SD, Schneider R. Chapter 57: Pulmonary involvement in the systemic inflammatory diseases of childhood. In: Kendig and Chernick’s disorders of the respiratory tract in children. Wilmott RW, Kendig EL, Boat TF, et al., eds. USA: Saunders Elsevier; 2012. pp. 822-847.; Okong'o LO, Scott C. The spectrum of paediatric rheumatic diseases in two tertiary centres in Cape Town, South Africa. Pediatr Rheumatol Online J. 2014;12(Suppl 1):155. doi:10.1186/1546-0096-12-S1-P155; Furia FF, Godfrey E, Mwamanenge N, et al. Spectrum of paediatric rheumatic disorders at a tertiary hospital in Tanzania. Pediatr Rheumatol. 2020;18:30. doi:10.1186/s12969-020-0418-2; Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(9842):689-698. doi:10.1016/S0140-6736(12)61079-4; Jee AS, Adelstein S, Bleasel J, et al. Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF). J Clin Med. 2017;6(5):51. doi:10.3390/jcm6050051; Nathan N, Corvol H, Amselem S, Clement A. Biomarkers in Interstitial lung diseases. Paediatr Respir Rev. 2015;16(4): 219-224. doi:10.1016/j.prrv.2015.05.002; Glasser SW, Hardie WD, Hagood JS. Pathogenesis of Interstitial Lung Disease in Children and Adults. Pediatr Allergy Immunol Pulmonol. 2010;23(1):9-14. doi:10.1089/ped.2010.0004; Myler HA, West JL. Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J Biochem. 2002;131(6):913-922. doi:10.1093/oxfordjournals.jbchem.a003182; Nicholson AG, Kim H, Corrin B, et al. The value of classifying interstitial pneumonitis in childhood according to defined histological patterns. Histopathology. 1998;33(3):203-211. doi:10.1046/j.1365-2559.1998.00488.x; Бойцова Е.В., Овсянников Д.Ю., Беляшова М.А. Педиатрические интерстициальные заболевания легких: дети не маленькие взрослые // Педиатрия. Журнал им. Г.Н. Сперанского. — 2015. — Т. 94. — №4. — С. 171-176.; Rovira E, Cuadras A, Aguilar X, et al. Asthma, respiratory symptoms and lung function in children living near a petrochemical site. Environ Res. 2014;133:156-163. doi:10.1016/j.envres.2014.05.022; Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: A review. Respirology. 2016;21(2): 245-258. doi:10.1111/resp.12588; Kumar A, Khan U, Shrestha B, et al. Interstitial lung disease as initial manifestation of systemic lupus erythematosus. J Nepal Health Res Counc. 2013;11(23):83-85. doi:10.33314/jnhrc.v0i0.358; Çiftçi E, Yalgnkaya F, ince E, et al. Pulmonary involvement in childhood-onset systemic lupus erythematosus: a report of five cases. Rheumatology. 2004;43(5):587-591. doi:10.1093/rheumatology/keh120; Tarvin SE, O'Neil RM. Systemic Lupus Erythematosus, Sjogren Syndrome and Mixed Connective Tissue Disease in Children and Adolescents. Pediatr Rheumatol North Am. 2018;65(4):711-738. doi:10.1016/j.pcl.2018.04.001; El-Shahawy EE-D, Morsy AF, Algoubashy AA, et al. Pleuropulmonary manifestations in juvenile onset systemic lupus erythematosus: assessment by pulmonary function tests and multidetector computed tomography. Egyptian Rheumatologist. 2011;33(4): 163-169. doi:10.1016/j.ejr.2011.06.001; Kurland G, Deterding RR, Hagood JS, et al. An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med. 2013;188(3):376-394. doi:10.1164/rccm.201305-0923ST; Bush A, Cunningham S, de Blic J, et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax. 2015;70(11):1078-1084. doi:10.1136/thoraxjnl-2015-207349; Koh DM, Hansell DM. Computed tomography of diffuse interstitial lung disease in children. Clin Radiol. 2000;55(9):659-667. doi:10.1053/crad.2000.0490; Guillerman RP. Imaging of Childhood Interstitial Lung Disease. Pediatr Allergy Immunol Pulmonol. 2010;23(1):43-68. doi:10.1089/ped.2010.0010; Panigada S, Ravelli A, Silvestri M, et al. HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatr Pulmonol. 2009;44(12):1226-1234. doi:10.1002/ppul.21141; Valeur NS, Stevens AM, Ferguson MR, et al. Multimodality thoracic imaging of juvenile systemic sclerosis: emphasis on clinical correlation and high resolution CT of pulmonary fibrosis. AJR Am J Roentgenol 2015;204(2):408-422. doi:10.2214/AJR.14.12461; Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971-3978. doi:10.1002/art.222073; Martini G, Vittadello F, Kasapçopur O, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford). 2009;48(2):119-122. doi:10.1093/rheumatology/ken388; Misra R, Singh G, Aggarwal P Aggarwal A. Juvenile onset systemic sclerosis: a single center experience of 23 cases from Asia. Clin Rheumatol. 2007;26(8):1259-1262. doi:10.1007/s10067-006-0483-z; Adrovic A, Şahin S, Barut K, Kasapçopur Ö. Juvenile Scleroderma: A Referral Center Experience. Arch Rheumatol. 2018;33(3): 344-351. doi:10.5606/ArchRheumatol.2018.6578; Foeldvari I, Tyndall A, Zulian F, et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology (Oxford). 2012;51(10):1832-1837. doi:10.1093/rheumatology/kes144; Russo RA, Katsicas MM. Clinical characteristics of children with Juvenile Systemic Sclerosis: follow-up of 23 patients in a single tertiary center. Pediatr Rheumatol Online J. 2007;5:6. doi:10.1186/1546-0096-5-6; Baildam EM, Ennis H, Foster HE, et al. Influence of childhood scleroderma on physical function and quality of life. J Rheumatol. 2011; 38(1):167-173. doi:10.3899/jrheum.100447; Guillot L, Flamein F, Thouvenin G, et al. BAL fluid surfactant protein C level is related to parenchymal lung disease in children with sarcoidosis. Chest. 2011;140(4):1104-1105. doi:10.1378/chest.11-0681; Kilinc AA, Arslan A, Yildiz M, et al. Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study. Rheumatol Int. 2020;40(10):1701-1706. doi:10.1007/s00296-019-04485-4; Kishaba T, McGill R, Nei Y, et al. Clinical characteristics of derma-tomyosits/polymyositis associated interstitial lung disease according to the autoantibody. J Med Invest. 2018;65(3.4):251-257. doi:10.2152/jmi.65.251; Morgenthau AS, Padilla ML. Spectrum of fibrosing diffuse parenchymal lung disease. Mt Sinai J Med. 2009;76(1):2-23. doi:10.1002/msj.20087; Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3): 814-824. doi:10.1378/chest.12-0741; Sanner H, Aalokken TM, Gran JT, et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. 2011;70(1):86-91. doi:10.1136/ard.2010.131433; Wu Q, Wedderburn LR, McCann LJ. Juvenile dermatomyositis: Latest advances. Best Pract Res Clin Rheumatol. 2017;31(4): 535-557. doi:10.1016/j.berh.2017.12.003; Fujisawa T, Hozumi H, Kono M, et al. Prognostic Factors for Myositis-Associated Interstitial Lung Disease. PLoS One. 2014; 9(6):e98824. doi:10.1371/journal.pone 0098824; Bai Y Tao XN. Research progress on amyopathic dermatomyositis associated with interstitial lung disease. Chin Med J (Engl). 2020; 133(1):111-113. doi:10.1097/CM9.0000000000000574; Ye Y Fu Q, Wang R, et al. Serum KL-6 level is a prognostic marker in patients with anti- MDA5 antibody-positive dermato-myositis associated with interstitial lung disease. J Clin Lab Anal. 2019;33(8):e22978. doi.org/10.1002/jcla.22978; Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med. 2007 Aug;28(4):451-8. doi:10.1055/s-2007-985666; Dubois’ Lupus Erythematosus and Related Syndromes. 9th ed. Wallace DJ, Hahn BH, eds. Elsiever; 2019. 816 p. doi:10.1016/C2015-0-06776-4; Quadrelli SA, Alvarez C, Arce SC, et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus. 2009;18(12):1053-1060. doi:10.1177/0961203309106601; Groot N, Graeff ND, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017;76(11):1788-1796. doi:10.1136/annrheumdis-2016-210960; Клюквина Н.Г., Асеева Е.А., Никонорова Н.О. Поражение легких при системной красной волчанке: хорошо известные факты и нерешенные вопросы // Научно-практическая ревматология. — 2016. — Т. 54. — № 5. — С. 578-589. doi:10.14412/1995-4484-2016-578-589; Wallace B, Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol. 2016; 28(3):236-245. doi:10.1097/BOR.0000000000000270; Alperin JM, Ortiz-Fernandez L, Sawalha AH. Monogenic Lupus: A Developing Paradigm of Disease. Front Immunol. 2018;9:2496. doi:10.3389/fimmu.2018.02496; Mina R, Brunner HI. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther. 2013;15(4):218. doi:10.1186/ar4256; Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4): 550-556. doi:10.1016/j.jpeds.2007.09.019; Sjogren’s syndrome. Wan-Fai NG, ed. Glasgow, UK: Oxford Unversity Press; 2016. 126 p.; Tomiita M, Saito K, Kohno Y et al. The clinical features of Sjogren's syndrome in Japanese children. Acta Paediatr Jpn. 1997; 39(2):268-272. doi:10.1111/j.1442-200x.1997.tb03597.x; Singer NG, Tomanova-Soltys I, Lowe R. Sjogren's syndrome in childhood. Curr Rheumatol Rep. 2008;10(2):147-155. doi:10.1007/s11926-008-0026-5; Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjogren's syndrome in comparison to adult Sjogren's syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016;34(2):343-351.; Virdee S., Greenan-Barrett J., Ciurtin C. A systematic review of primary Sjogren's syndrome in male and paediatric populations. Clin Rheumatol. 2017;36(10):2225-2236. doi:10.1007/s10067-017-3745-z; Yazisiz V, Arslan G, Ozbudak IH, et al. Lung involvement in patients with primary Sjogren's syndrome: what are the predictors? Rheumatol Int. 2010;30(10):1317-1324. doi:10.1007/s00296-009-1152-8; Palm O, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality: a retrospective study based on registry data. Rheumatology (Oxford). 2013;52(1):173-179. doi:10.1093/rheumatology/kes311; Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjogren syndrome. Chest. 2006;130(5):1489-1495. doi:10.1378/chest.130.5.1489; Ramos-Casals M, Brito-Zeron P, Font J. The overlap of Sjogren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36(4):246-255. doi:10.1016/j.semarthrit.2006.08.007; La Torre F, Martini G, Russo R, et al. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum. 2012;64(12):4143-4150. doi:10.1002/art.34652; Hoffmann-Vold A-M, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statement. Lancet. 2020;2(2):E71-E83. doi:10.1016/S2665-9913(19)30144-4; Distler O, Highland KB, Gahlemann M, et al. Nintedanib in systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. doi:10.1056/NEJMoa1903076; Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18):1718-1727. doi:10.1056/NEJMoa1908681; Glasser SW, Hagood JS, Wong S, et al. Mechanisms of Lung Fibrosis Resolution. Am J Pathol. 2016;186(5):1066-1077. doi:10.1016/j.ajpath.2016.01.018; Ferraro VA, Zanconato S, Zamunaro A, Carraro S. Children's Interstitial and Diffuse Lung Diseases (ChILD) in 2020. Children (Basel). 2020;7(12):280. doi:10.3390/children7120280; Deterding RR, DeBoer EM, Cidon MJ, et al. Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019;200(10):1219-1227. doi:10.1164/rccm.201903-0544CI; Boehringer Ingelheim. A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD). April 9, 2021. Available online: https://clinicaltrials.gov/ct2/show/ NCT04093024. Accessed on April 14, 2021.; Легочная гипертензия у детей: клинические рекомендации. 2017. Доступно по: https://legalacts.ru/doc/klinicheskie-reko-mendatsii-legochnaja-gipertenzija-u-detei-utv-minzdravom-rossii. Ссылка активна на 14.04.2021.

Διαθεσιμότητα: https://vsp.spr-journal.ru/jour/article/view/2596
https://doi.org/10.15690/vsp.v20i2.2257

Interstitial lung disease in systemic sclerosis (systemic scleroderma) ; Интерстициальные заболевания легких при системном прогрессирующем склерозе (системной склеродермии)

Συγγραφείς: L. P. Ananyeva, I. E. Tyurin, O. A. Koneva, L. A. Garzanova, A. M. Lila, Л. П. Ананьева, И. Е. Тюрин, О. А. Конева, Л. А. Гарзанова, А. М. Лила

Πηγή: Modern Rheumatology Journal; Том 15, № 1S (2021); 1-62 ; Современная ревматология; Том 15, № 1S (2021); 1-62 ; 2310-158X ; 1996-7012

Θεματικοί όροι: лечение, interstitial lung disease, lung function tests, high-resolution computed tomography, diagnostics, treatment, интерстициальное поражение легких, функциональные легочные тесты: компьютерная томография высокого разрешения, диагностика

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1114/1074; Manetti M, Matucci-Cerinic M. The new frontier in systemic sclerosis: from epigenetics to new treatments. Rheumatology (Oxford). 2015 Oct;54(10):1757-8. doi:10.1093/rheumatology/kev264. Epub 2015 Jul 30.; Bossini-Castillo L, Lopez-Isac E, Mayes MD, Martin J. Genetics of systemic sclerosis. Semin Immunopathol. 2015 Sep;37(5):443-51. doi:10.1007/s00281-015-0499-z. Epub 2015 Jun 2.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.; Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012 Jun;51(6):1017-26. doi:10.1093/rheumatology/ker269. Epub 2011 Sep 7.; Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003 Aug;48(8):2246-55. doi:10.1002/art.11073.; Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007 Jul;66(7):940-4. doi:10.1136/ard.2006.066068.; Nyhtyanova SI, Schreiber BE, Ong VN, et.al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014 Jun;66(6):1625-35. doi:10.1002/art.38390.; Volkmann ER, Tashkin DP, Sim M, et al. groups SIaSIs. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2019 Jan;78(1):122-130. doi:10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8.; Nichtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM. 2010 Feb;103(2):109-15. doi:10.1093/qjmed/hcp174. Epub 2009 Dec 4.; Sverzellati N, Lynch DA, Hansell DM, et al. American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. Radiographics. Nov-Dec 2015;35(7):1849-71. doi:10.1148/rg.2015140334.; Nathan N, Corvol H, Amselem S, Clement A. Biomarkers in Interstitial lung diseases. Paediatr Respir Rev. 2015 Sep;16(4):219-24. doi:10.1016/j.prrv.2015.05.002. Epub 2015 May 12.; Hunzelmann N, Brinckmann J. What are the milestones in the pathogenesis of systemic sclerosis? Ann Rhеum Dis. 2010; 69 Suppl: i52–i56. doi:10.1136/ard.2009.1171191-4.; Gasser SW, Hardie WD, Hagood JS. Pathogenesis of interstitial disease in children and adult. Pediatr Allergy Immunol Pulmonol. 2010 Mar;23(1):9-14. doi:10.1089/ped.2010.0004.; Clement A, Eber E. Interstitial lung diseases in infants and children. Eur Respir J. 2008 Mar;31(3):658-66. doi:10.1183/09031936.00004707.; Hoffmann-Vold AM, Weigt SS, Saggar R, et al. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. EBioMedicine. 2019 Dec;50: 379-386. doi:10.1016/j.ebiom.2019.10.050.; Richeldi L, Varone F, Bergna M, et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018 Dec 21; 27(150):180074. doi:10.1183/16000617.0074-2018. Print 2018 Dec 31.; Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018 May 17;51(5):1800692. doi:10.1183/13993003.00692-2018. Print 2018 May.; Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019 Feb 27;28(151):180100. doi:10.1183/16000617.0100-2018. Print 2019 Mar 31.; Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019 Jan 18;20(1):13. doi:10.1186/s12931-019-0980-7.; Travis WD, Costabel U, Hansell DM, et al. An ofcial American Toracic Society/European Respiratory Society statement: Update of the international multidisciplinary classifcation of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15;188(6): 733-48. doi:10.1164/rccm.201308-1483ST.; Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST.; Travis WD, Hunninghake G, King TEJ, Lynch DA, et al. Idiopathic nonspecific interstitial pneumonia: Report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008 Jun 15;177(12):1338-47. doi:10.1164/rccm.200611-1685OC. Epub 2008 Apr 3.; Todd NW, Marciniak ET, Sachdeva A, et al. Organizing pneumonia/non-specific interstitial pneumonia overlap is associated with unfavorable lung disease progression. Respir Med. 2015 Nov;109(11):1460-8. doi:10.1016/j.rmed.2015.09.015. Epub 2015 Oct 9.; Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1581-6. doi:10.1164/rccm.2106012.; Park JH, Kim DS, Park I, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007 Apr 1; 175(7):705-11. doi:10.1164/rccm.200607-912OC. Epub 2007 Jan 11.; Baha A, Yildirim F, Kö ktü rk N, et al. Cryptogenic and Secondary Organizing Pneumonia: Clinical Presentation, Radiological and Laboratory Findings, Treatment, and Prognosis in 56 Cases. Turk Thorac J. 2018 Sep 13;19(4):201-208. doi:10.5152/TurkThoracJ.2018.18008.; Adegunsoye A, Oldham JM, Bellam SK, et al. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Ann Am Thorac Soc. 2019 May;16(5):580-588. doi:10.1513/AnnalsATS.201807-443OC.; Steen VD, Conte C, Owens GR, Medsgar TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994 Sep;37(9):1283-9. doi:10.1002/art.1780370903.; Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2020 Sep 28;annrheumdis-2020-217455. doi:10.1136/annrheumdis-2020- 217455. Online ahead of print.; Rubio-Rivas M, Royo C, Simeon CP, et al. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Oct;44(2):208-19. doi:10.1016/j.semarthrit.2014.05.010. Epub 2014 May 14.; Van den Hoogen F, Khanna D, Fransen J, et al. Classification criteria for systemic sclerosis: An ACR-EULAR collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737-47. doi:10.1002/art.38098. Epub 2013 Oct 3.; Ананьева ЛП, Александрова ЕН. Аутоантитела при системной склеродермии: спектр, клинические ассоциации и прогностическое значение. Научно-практическая ревматология. 2016;54(1):86-99.; Bankier AA, O’Donnell CR, Boiselle PM. Quality initiatives. Respiratory instructions for CT examinations of the lungs: a hands-on guide. Radiographics. Jul-Aug 2008;28(4): 919-31. doi:10.1148/rg.284085035.; Remy-Jardin M, Campistron P, Amara A, et al. Usefulness of coronal reformations in the diagnostic evaluation of infiltrative lung disease. J Comput Assist Tomogr. Mar 2003;27(2): 266-73. doi:10.1097/00004728-200303000-00028.; Johkoh T, Sakai F, Noma S, et al. Honeycombing on CT; its definition, pathologic correlation, and future direction of its diagnosis. Eur J Radiol. 2014 Jan;83(1):27-31. doi:10.1016/j.ejrad.2013.05.012. Epub 2013 Jun 24.; Bankier AA, Tack D. Dose reduction strategies for thoracic multidetector computed tomography: background, current issues, and recommendations. J Thorac Imaging. 2010 Nov;25(4):278-88. doi:10.1097/RTI.0b013e3181eebc49.; Pontana F, Billard AS, Duhamel A, et al. Effect of iterative reconstruction on the detection of systemic sclerosis-related interstitial lung disease: clinical experience in 55 patients. Radiology. 2016 Apr;279(1):297-305. doi:10.1148/radiol.2015150849. Epub 2015 Nov 18.; Hansell DM. Thin-section CT of the lungs: the Hinterland of normal. Radiology. 2010 Sep;256(3):695-711. doi:10.1148/radiol.10092307.; Kim M, Lee SM, Song JW, et al. Added value of prone CT in the assessment of honeycombing and classification of usual interstitial pneumonia pattern. Eur J Radiol. 2017 Jun; 91:66-70. doi:10.1016/j.ejrad.2017.03.018. Epub 2017 Mar 30.; Tokura S, Okuma T, Akira M, et al. Utility of expiratory thin-section CT for fibrotic interstitial pneumonia. Acta Radiol. 2014 Nov;55(9):1050-5. doi:10.1177/0284185113512300. Epub 2013 Nov 19.; Gotway MB, Lee ES, Reddy GP, et al. Low-dose, dynamic, expiratory thin-section CT of the lungs using a spiral CT scanner. J Thorac Imaging. 2000 Jul;15(3):168-72. doi:10.1097/00005382-200007000-00003.; Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances on thinsection computed tomography in fibrosing alveolitis. Am Rev Respir Dis. 1993 Oct; 148(4 Pt 1):1076-82. doi:10.1164/ajrccm/148.4_Pt_1.1076.; Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005 Aug 15;172(4): 488-93. doi:10.1164/rccm.200412-1756OC. Epub 2005 May 13.; Shin KM, Lee KS, Chung MP, et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology. 2008 Oct;249(1):328-37. doi:10.1148/radiol.2483071378. Epub 2008 Aug 5.; Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008 Mar;246(3):697-722. doi:10.1148/radiol.2462070712. Epub 2008 Jan 14.; Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology. 2013 Mar;266(3):936-44. doi:10.1148/radiol.12112516. Epub 2012 Dec 6.; Jacob J, Hansell DM. HRCT of fibrosing lung disease. Respirology. 2015 Aug;20(6):859-72. doi:10.1111/resp.12531. Epub 2015 Apr 21.; Staats P, Kligerman S, Todd N, et al. A comparative study of honeycombing on high resolution computed tomography with histologic lung remodeling in explants with usual interstitial pneumonia. Pathol Res Pract. 2015 Jan;211(1):55-61. doi:10.1016/j.prp.2014.08.013. Epub 2014 Oct 22.; Edey AJ, Devaraj AA, Barker RP, et al. Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol. 2011 Aug;21(8):1586-93. doi:10.1007/s00330-011-2098-2. Epub 2011 Mar 6.; Piciucchi S, Tomassetti S, Ravaglia C, et al. From «traction bronchiectasis» to honeycombing in idiopathic pulmonary fibrosis: a spectrum of bronchiolar remodeling also in radiology? BMC Pulm Med. 2016 May 23;16(1):87. doi:10.1186/s12890-016-0245-x.; Remy-Jardin M, Giraud F, Remy J, et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology. 1993 Dec;189(3):693-8. doi:10.1148/radiology.189.3.8234692.; Souza CA, Mü ller NL, Lee KS, et al. Idiopathic interstitial pneumonias: prevalence of mediastinal lymph node enlargement in 206 patients. AJR Am J Roentgenol. 2006 Apr; 186(4):995-9. doi:10.2214/AJR.04.1663.; Kim TS, Han J, Chung MP, et al. Disseminated dendriform pulmonary ossification associated with usual interstitial pneumonia: incidence and thin-section CT-pathologic correlation. Eur Radiol. 2005 Aug;15(8):1581-5. doi:10.1007/s00330-005-2671-7. Epub 2005 Apr 23.; Egashira R, Jacob J, Kokosi MA, et al. Diffuse pulmonary ossification in fibrosing interstitial lung diseases: prevalence and associations. Radiology. 2017 Jul;284(1):255-263. doi:10.1148/radiol.2017152419. Epub 2017 Feb 9.; Reddy TL, Tominaga M, Hansell DM, et al. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. Eur Respir J. 2012 Aug;40(2):377-85. doi:10.1183/09031936.00165111. Epub 2012 Mar 22.; Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med. 2008 Feb 15;177(4):433-9. doi:10.1164/rccm.200611-1696OC. Epub 2007 Nov 1.; Capobianco J, Grimberg A, Thompson BM, et al. Thoracic manifestations of collagen vascular diseases. Radiographics. Jan-Feb 2012;32(1):33-50. doi:10.1148/rg.321105058.; Nagai S, Handa T, Tabuena R, et al. Nonspecific interstitial pneumonia: a real clinical entity? Clin Chest Med. 2004 Dec;25(4):705-15, vi. doi:10.1016/j.ccm.2004.04.009.; Egashira R, Kondo T, Hirai T, et al. CT findings of thoracic manifestations of primary Sjogren syndrome: radiologicpathologic conrelation. Radiographics. Nov-Dec 2013;33(7): 1933-49. doi:10.1148/rg.337125107.; Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19. doi:10.1164/rccm.201506-1063ST.; Wells AU, Margaritopoulos GA, Antoniou KM, Denton C. Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med. 2014 Apr;35(2):213-21. doi:10.1055/s-0034-1371541. Epub 2014 Mar 25.; Гриппи МА, редактор. Патофизиология легких. Москва: БИНОМ; 2005. С. 58-78.; Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. 2015 May;41(2):237-48. doi:10.1016/j.rdc.2014.12.005.; Showalter K, Hoffmann A, Rouleau G, et al. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis. J Rheumatol. 2018 Nov;45(11):1572-1576. doi:10.3899/jrheum.171362. Epub 2018 Oct 1.; Теплова ЛВ, Ананьева ЛП, Лесняк ВН и др. Системная склеродермия с интерстициальным поражением легких: сравнительная клиническая характеристика с больными без поражения легких. Научно-практическая ревматология. 2010;48(3):41-47.; Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000 Nov;43(11):2437-44. doi:10.1002/1529-0131(200011)43:113.0.CO;2-U.; Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009 Nov;136(5): 1333-1340. doi:10.1378/chest.09-0108.; Nakamura Y, Chida K, Suda T, et al. Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2003 Oct;20(3):235-41.; Wells AU, Rubens MB, du Bois RM, Hansell DM. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol. 1993 Dec;161(6):1159-65. doi:10.2214/ajr.161.6.8249719.; Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi:10.1016/j.jacc.2013.10.032.; Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol. 2015 Sep;37(5): 489-500. doi:10.1007/s00281-015-0505-5. Epub 2015 Jul 8.; Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003 Feb;48(2):516-22. doi:10.1002/art.10775.; Man A, Davidyock T, Ferguson LT, et al. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling. Rheumatology (Oxford). 2015 Aug;54(8):1464-71. doi:10.1093/rheumatology/kev016. Epub 2015 Mar 17.; Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011 Oct;63(10):3078-85. doi:10.1002/art.30467.; Tyndall A, Gratwohl AD. Adult stem cell transplantation in autoimmune disease. Curr Opin Hematol. 2009 Jul;16(4):285-91. doi:10.1097/MOH.0b013e32832aacb3.; Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi:10.1002/art.40130.; Khanna D, Tseng CH, Farmani N, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther. 2015 Dec 23;17:372. doi:10.1186/s13075-015-0872-2.; Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi:10.1056/NEJMoa1908681. Epub 2019 Sep 29.; Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J. 2010 Jan;35(1):112-7. doi:10.1183/09031936.00060209. Epub 2009 Jun 18.; Suliman YA, Dobrota R, Huscher D, et al. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. Arthritis Rheumatol. 2015 Dec;67(12):3256-61. doi:10.1002/art.39405.; Hoffmann-Vold AM, Aal∅kken TM, Lund MB, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol. 2015 May;67(8):2205-12. doi:10.1002/art.39166.; Cappelli S, Bellando Randone S, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev. 2015 Sep;24(137):411-9. doi:10.1183/16000617.00002915.; Hoffmann-Vold AM, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2020;9913(2): E71-E83. doi:10.1016/S2665-9913(19)30144-4; Hoffmann-Vold AM, Allanore Y, Bendstrup E, et al. The need for a holistic approach for SScILD – achievements and ambiguity in a devastating disease. Respir Res. 2020 Jul 23;21(1):197. doi:10.1186/s12931-020-01459-0.; Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2013 Jan;52(1):155-60. doi:10.1093/rheumatology/kes289; Goh N, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54. doi:10.1164/rccm.200706-877OC; Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016 Oct 5;11(10):e0163894. doi:10.1371/journal.pone.0163894. eCollection 2016.; Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019 Nov;35(11): 2015-24. doi:10.1080/03007995.2019.1647040. Epub 2019 Aug 2.; Iudici M, Fasano S, Iacono D, et al. Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol. 2014 Feb;33(2):153-64. doi:10.1007/s10067-013-2422-0. Epub 2013 Nov 19.; Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9.; Fernandez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018 Nov;70(11): 1820-28. doi:10.1002/art.40560. Epub 2018 Sep 17.; Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung diseaseindividualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018 Jan 30;20(1):17. doi:10.1186/s13075-018-1517-z.; Нoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006 Dec;54(12):3962-70. doi:10.1002/art.22204.; Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655-66. doi:10.1056/NEJMoa055120.; Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 2011 Sep;63(9): 2797-808. doi:10.1002/art.30438.; Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009 Nov; 136(5):1333-1340. doi:10.1378/chest.09-0108.; Van den Hombergh WMT, Simons SO, Teesselink E, et al. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function. Clin Rheumatol. 2018 Oct;37(10):2715-22. doi:10.1007/s10067-018-4171-6. Epub 2018 Jul 10.; Volkmann ER, Tashkin DP, Sim M, et al. Cyclophosphamide for Systemic Sclerosisrelated Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. J Rheumatol. 2019 Oct;46(10):1316-25. doi:10.3899/jrheum.180441. Epub 2019 Feb 15.; Dan D, Fischer R, Adler S, et al. Cyclophosphamide: as bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases. Swiss Med Wkly. 2014 Oct 23;144:w14030. doi:10.4414/smw.2014.14030. eCollection 2014.; Omair MA, Alahmadi A, Johnson SR. Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS One. 2015 May 1;10(5):e0124205. doi:10.1371/journal.pone.0124205. eCollection 2015.; Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in sclerodermarelated interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708-719. doi:10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.; Pavlov-Dolijanovic S, Vujasinovic Stupar N, Zugic V, et al. Long-term effects of immunosuppressive therapy on lung function in scleroderma patients. Clin Rheumatol. 2018 Nov; 37(11):3043-3050. doi:10.1007/s10067-018-4266-0. Epub 2018 Aug 24.; Burt RK, Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis:history and current status. Curr Opin Rheumatol. 2011 Nov;23(6):519-29. doi:10.1097/BOR.0b013e32834aa45f.; Van Laar JM, Farge D, Sont JK, et al. Autologous haemopoetic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014 Jun 25;311(24):2490-8. doi:10.1001/jama.2014.6368.; Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative hemotopoetic stem-cell transplantation compared with pulse cyclophosphamide once per months for systemic sclerosis (ASSIST): an open label. Randomized phase 2 trial. Lancet. 2011 Aug 6; 378(9790):498-506. doi:10.1016/S0140-6736(11)60982-3. Epub 2011 Jul 21.; Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018 Jan 4;378(1):35-47. doi:10.1056/nejmoa1703327.; Farge D, Burt RK, Oliveire MC, et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party and collaborating partners. Bone Marrow Transplant. 2017 Nov;52(11):1495-503. doi:10.1038/bmt.2017.56. Epub 2017 May 22.; Del Papa N, Pignataro F, Zaccara E, et al. Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis. Front Immunol. 2018 Oct 16;9:2390. doi:10.3389/fimmu.2018.02390. eCollection 2018.; Snowden JA, Badoglio M, Labopin M, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017 Dec 20;1(27):2742-2755. doi:10.1182/bloodadvances.2017010041. eCollection 2017 Dec 26.; Khanna D, Tashkin DP, Denton CP, et al. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2019 Apr 1;58(4):567-579. doi:10.1093/rheumatology/key151.; Giuggioli D, Lumetti F, Colaci Met al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015 Nov; 14(11):1072-8. doi:10.1016/j.autrev.2015.07.008. Epub 2015 Jul 22.; Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017 Apr;46(5):625-631. doi:10.1016/j.semarthrit.2016.10.003. Epub 2016 Oct 13.; Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015 Jun;74(6):1188-94. doi:10.1136/annrheumdis-2013-204522. Epub 2014 Jan 17.; Sircar G, Goswami RP, Sircar D, et al. Intravenous Cyclophosphamide vs Rituximab for the Treatment of Early Diffuse Scleroderma Lung Disease: Open Label, Randomized, Controlled Trial. Rheumatology (Oxford). 2018 Dec 1;57(12):2106-13. doi:10.1093/rheumatology/key213.; Ананьева ЛП, Конева ОА, Десинова ОВ и др. Влияние ритуксимаба на проявления активности и легочную функцию у больных системной склеродермией: оценка после года наблюдения. Научно-практическая ревматология. 2019;57(3):265-73.; Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017 Jun 15;18(1):275. doi:10.1186/s13063-017-2016-2.; O’Reilly S, Cant R, Ciechomska M, van Laar JM. Interleukin-6: a newtherapeutic target in systemic sclerosis? Clin Transl Immunology. 2013 Apr 12;2(4):e4. doi:10.1038/cti.2013. 2. eCollection 2013 Apr.; Shima Y,Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford). 2010 Dec;49(12):2408-12. doi:10.1093/rheumatology/keq275. Epub 2010 Sep 5.; Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013 Jul;72(7):1217-20. doi:10.1136/annrheumdis2012-202657. Epub 2012 Dec 19.; Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016 Jun 25;387(10038):2630-40. doi:10.1016/S0140-6736(16)00232-4. Epub 2016 May 5.; Khanna D, Lin CJF, Kuwana M, et al. Efficacy and Safety of Tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial. Arthritis Rheumatol. 2018;70 (suppl 10):898.; Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018 Feb;77(2):212-20. doi:10.1136/annrheumdis2017-211682. Epub 2017 Oct 24.; Zacay G, Levy Y. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. Best Pract Res Clin Rheumatol. 2018 Aug;32(4): 563-71. doi:10.1016/j.berh.2019.01.011. Epub 2019 Feb 21.; Sierra-Sepulveda A, Esquinca-Gonzalez A, Benavides-Suarez SA, et al. Systemic Sclerosis Pathogenesis and Emerging Therapies,beyond the Fibroblast. Biomed Res Int. 2019 Jan 23;2019:4569826. doi:10.1155/2019/4569826. eCollection 2019.; Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitornintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014 May;349(2):209-20. doi:10.1124/jpet.113.208223. Epub 2014 Feb 20.; Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015 May;45(5):1434-45. doi:10.1183/09031936.00174914. Epub 2015 Mar 5.; Tandon K, Herrmann FE, Ayaub E, et al. Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor. Am J Respir Crit Care Med. 2017;195:A2397.; Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016 May;75(5):883-90. doi:10.1136/annrheumdis-2014-207109. Epub 2015 Apr 9.; Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017 Nov;76(11):1941-48. doi:10.1136/annrheumdis-2016-210823. Epub 2017 Aug 16.; Wollin L, Ostermann A, Williams C. Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease. Eur Respir J. 2017;50:Suppl. 61:PA903.; Distler O, Highland KB, Gahlemann M, et al. Nintedanib in systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi:10.1056/NEJMoa1903076. Epub 2019 May 20.; Авдеев СН, Ананьева ЛП, Жиляев ЕВ и др. Резолюция Совета экспертов, посвященная теме «Интерстициальные заболевания легких при системной скелродермии» (14 октября 2019 г.). Современная ревматология. 2020;14(1):125-8.; https://clinicaltrials.gov/ct2/show/NCT02745145; https://clinicaltrials.gov/ct2/show/NCT00574613; Rice LM, Padilla CM, McLaughlin SR, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015 Jul 1;125(7):2795-807. doi:10.1172/JCI77958. Epub 2015 Jun 22.; Khanna D. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol. 2016 Sep;43(9):1672-9. doi:10.3899/jrheum.151322. Epub 2016 Jul 1.; Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 Jan;34(1):1-15. doi:10.1016/j.healun.2014.06.014. Epub 2014 Jun 26.; Bernstein EJ, Peterson ER, Sell JL, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 2015 May;67(5): 1314-22. doi:10.1002/art.39021.; Khan IY, Singer LG, de Perrot M, et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med. 2013 Dec;107(12):2081-7. doi:10.1016/j.rmed.2013.09.015. Epub 2013 Sep 26.; Crespo MM, Bermudez CA, Dew MA, et al. Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis. Short- and Long-Term Outcomes. Ann Am Thorac Soc. 2016 Jun;13(6):784-92. doi:10.1513/AnnalsATS.201503-177OC.; Miele CH, Schwab K, Saggar R, et al. Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. Ann Am Thorac Soc. 2016 Jun;13(6):793-802. doi:10.1513/AnnalsATS.201512-806OC.; Fernandez-Codina A, Berastegui C, Pinal-Fernandez I, et al. Lung transplantation in systemic sclerosis: A single center cohort study. Joint Bone Spine. 2018 Jan;85(1):79-84. doi:10.1016/j.jbspin.2017.03.012. Epub 2017 Apr 11

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1114
https://doi.org/10.14412/1996-7012-2021-1S-1-62

Пример дифференциальной диагностики интерстициального поражения легких при системном васкулите ; An example of the differential diagnosis of interstitial lung disease in patient with widespread vasculitis

Συγγραφείς: Bannova, I. I., Akimova, A. V., Popov, A. A., Баннова, И. И., Акимова, А. В., Попов, А. А.

Πηγή: Сборник статей

Θεματικοί όροι: INTERSTITIAL LUNG DISEASE, WIDESPREAD VASCULITIS, DIAGNOSTICS, ИНТЕРСТИЦИАЛЬНОЕ ПОРАЖЕНИЕ ЛЕГКИХ, СИСТЕМНЫЙ ВАСКУЛИТ, ДИАГНОСТИКА

Περιγραφή αρχείου: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей IV Международной научно-практической конференции молодых учёных и студентов, IV Всероссийского форума медицинских и фармацевтических вузов «За качественное образование», (Екатеринбург, 10-12 апреля 2019): в 3-х т. - Екатеринбург: УГМУ, CD-ROM.; http://elib.usma.ru/handle/usma/3736

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/3736

Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation ; Влияние ритуксимаба на проявления активности и легочную функцию у больных системной склеродермией: оценка после года наблюдения

Συγγραφείς: L. P. Ananyeva, O. A. Koneva, O. V. Desinova, L. A. Garzanova, S. I. Glukhova, M. N. Starovoitova, O. B. Ovsyannikova, A. V. Volkov, A. P. Aleksankin, E. L. Nasonov, Л. П. Ананьева, О. А. Конева, О. В. Десинова, Л. А. Гарзанова, С. И. Глухова, М. Н. Старовойтова, О. Б. Овсянникова, А. В. Волков, А. П. Алексанкин, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 57, No 3 (2019); 265-273 ; Научно-практическая ревматология; Vol 57, No 3 (2019); 265-273 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: ритуксимаб, interstitial lung disease, anti-B cell therapy, rituximab, интерстициальное поражение легких, анти-В-клеточная терапия

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2724/1840; Bosello S, De Luca G, Tolusso B, et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev. 2011;10(10):624-30. doi:10.1016/j.autrev.2011.04.013; Yoshizaki A, Sato S. Abnormal B lymphocyte activation and function in systemic sclerosis. Ann Dermatol. 2015;27:1-9. doi:10.5021/ad.2015.27.1.1; Sakkas LL, Dimitrios P, Bogdanos DP. The Role of B cells in the Pathogenesis of systemic sclerosis. IMAJ. 2016;18:516-8.; Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018;195:76-82. doi:10.1016/j.imlet.2018.01.002; Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578-83. doi:10.1002/art.24249; Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up openlabel trial. Arthritis Res Ther. 2010;12(2):54. doi:10.1186/ar2965; Smith V, van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193-7. doi:10.1136/ard.2008.095463; Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52-5. doi:10.3899/jrheum.120778; Giuggioli D, Lumetti F, Colaci M, et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015;14(11):1072-8. doi:10.1016/j.autrev.2015.07.008; Ананьева ЛП, Соловьев СК, Бекетова ТВ и др. Анти-В-клеточная терапия при системных аутоиммунных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495-506 [Ananieva LP, Soloviyov SK, Beketova TV, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):495-506 (In Russ.)]. doi:10.14412/1995-4484-2014-495-506; Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatol (Oxford). 2012;51:1017-26. doi:10.1093/rheumatology/ker269; Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-55. doi:10.1136/annrheumdis-2013-204424; Walker UA, Tyndall A, Czirjak L, et al Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66(6):754-63. doi:10.1136/ard.2006.062901; Gazi H, Pope JE, Clements P, et al. Outcome measurements in scleroderma: results from a delphi exercise. J Rheumatol. 2007;34:501-9.; Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum. 2000;43:2445-54. doi:10.1002/1529-0131(200011)43:113.0.CO;2-Q; Khanna D, Furst DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis. 2006;65:1325-9. doi:10.1136/ard.2005.050187; Vallentini G, Della Rossa A, Bombardier S, et al. European multicentre study of define disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592-8. doi:10.1136/ard.60.6.592; Behr J, Furst DE. Pulmonary function tests. Rheumatology (Oxford). 2008;47(5):65-7. doi:10.1093/rheumatology/ken313; Khanna D, Seibold J, Goldin J, et al. Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology (Oxford). 2017;56(5):27-32. doi:10.1093/rheumatology/kex203; Kafaja S, Clements PJ, Wilhalme H, et al. Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med. 2018;197(5):644-52. doi:10.1164/rccm.201709-1845OC; ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7. doi:10.1164/ajrccm.166.1.at1102; Dass S, Rawstron AC, Vital EM, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58:2993-9. doi:10.1002/art.23902; Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620-9. doi:10.1136/ard.2008.096677; Khanna D, Distler JHW, Sandner P, et al. Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord. 2016;1:186-93. doi:10.5301/jsrd.5000207; Sakkas LI, Bogdanos DP. Systemic sclerosis: New evidence reinforces the role of B cells. Autoimmune Rev. 2016;15:155-61. doi:10.1016/j.autrev.2015.10.005; Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):17-22.; Jordan S, Distler JH, Maurer B, et al; EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 201;74(6):1188-94. doi:10.1136/annrheumdis-2013-204522; Lepri G, Avouac J, Airo P, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016;34 Suppl 100(5):181-5.; Boonstra M, Meijs J, Dorjee AL, Marsan NA. Rituximab in early systemic sclerosis. RMD Open. 2017;3(2):384. doi:10.1136/rmdopen-2016-000384. eCollection 2017.; Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428-36.; Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46(5):625-31.; Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung disease – individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20:17. doi:10.1186/s13075-018-1517; Lee JJ, Pope JE. Diagnosis and management of systemic sclerosis: a practical approach. Drug. 2016;76:203-13. doi:10.1007/s40265-015-0491-x; Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther. 2017;11:2891-904. doi:10.2147/DDDT.S139248; Насонов ЕЛ, редактор. Российские клинические рекоменда- ции. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya. [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)].; Merkel PA, Silliman NP, Clements P, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2012;64:3420-9. doi:10.1002/art.34427; Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100:485-94. doi:10.1093/qjmed/hcm052; Thiebaut M, Launay D, Riviere S, et al. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev. 2018;17(6):582-7. doi:10.1016/j.autrev.2017.12.010; Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trail of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962-70. doi:10.1002/art.22204; Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Eng J Med. 2006;354(25):2655-66. doi:10.1056/NEJMoa055120; Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a doubleblind, parallel group, randomized controlled trial. Lancet Respir Med. 2016;4(9):708-19. doi:10.1016/S2213-2600(16)30152-7; Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003;62:146-50. doi:10.1136/ard.62.2.146; Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581-6. doi:10.1164/rccm.2106012; Colp CR, Riker J, Williams MH Jr. Serial changes in scleroderma and idiopathic interstitial lung disease. Arch Intern Med. 1973;132(4):506-15. doi:10.1001/archinte.1973.03650100028006; Greenwald GI, Tashkin DP, Gong H, et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am J Med. 1987;83(1):83-92. doi:10.1016/0002-9343(87)90501-8; Schneider PD, Wise RA, Hochberg MC, Wigley FM. Serial pulmonary function in systemic sclerosis. Am J Med. 1982;73:385-94. doi:10.1016/0002-9343(82)90732-X; Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283-9. doi:10.1002/art.1780370903; Assassi S, Sharif R, Lasky RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther. 2010;12:166. doi:10.1186/ar3125; Man A, Davidyock T, Ferguson LT, et al. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling. Rheumatology (Oxford). 2015;54(8):1464-71. doi:10.1093/rheumatology/kev016; Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011;63(10):3078-85. doi:10.1002/art.30467; Fernandez-Codina A, Walker KM, Pope JE. Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheum. 2018;70(11):1820-8. doi:10.1002/art.40560. Epub 2018 Sep 17.; Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-39. doi:10.1136/annrheumdis-2016-209909; Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): study protocol for a randomized controlled trial. Trials. 2017;18:275-86. doi:10.1186/s13063-017-2016-2

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2724
https://doi.org/10.14412/1995-4484-2019-265-273

Оценка краткосрочной динамики общего числа В-лимфоцитов на фоне лечения ритуксимабом больных системной склеродермией

Πηγή: Научно-практическая ревматология, Vol 0, Iss 0 (2018)

Θεματικοί όροι: системная склеродермия, интерстициальное поражение легких, анти-в-клеточная терапия, в-лимфоциты, ритуксимаб, дозировка, Diseases of the musculoskeletal system, RC925-935

Περιγραφή αρχείου: electronic resource

Relation: https://rsp.mediar-press.net/rsp/article/view/2826; https://doaj.org/toc/1995-4484; https://doaj.org/toc/1995-4492

Σύνδεσμος πρόσβασης: https://doaj.org/article/96ac5ac368d741e3979f43bf1e0f245e

THE IMPORTANCE OF HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN EVALUATING THE EFFICACY OF RITUXIMAB IN PATIENTS WITH INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS ; Значение компьютерной томографии высокого разрешения в оценке эффективности ритуксимаба у пациентов с интерстициальным поражением легких при системной склеродермии

Συγγραφείς: O. A. Koneva, O. V. Desinova, L. P. Ananyeva, N. V. Kovaleva, О. А. Конева, О. В. Десинова, Л. П. Ананьева, Н. В. Ковалева

Πηγή: Rheumatology Science and Practice; Vol 56, No 5 (2018); 591-599 ; Научно-практическая ревматология; Vol 56, No 5 (2018); 591-599 ; 1995-4492 ; 1995-4484 ; undefined

Θεματικοί όροι: функциональные легочные тесты, interstitial lung disease, multi-slice spiral computed tomography, pulmonary function tests, интерстициальное поражение легких, мультиспиральная компью- терная томография

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2623/1757; Varga J, Abraham D. Systemic sclerosis: prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-67. doi:10.1172/JCI31139; Wells AU. Interstitial lung disease in systemic sclerosis. Presse Мed. 2014;43:329-43. doi:10.1016/j.lpm.2014.08.002; Capelli S, Bellando Randone S, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev. 2015;24(137):411-9. doi:10.1183/16000617.00002915; Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis. 1972–2002. Ann Rheum Dis. 2007;66:940-4. doi:10.1136/ard.2006.066068; Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809-15. doi:10.1136/ard.2009.114264; Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006;55(4):598-602.; Fransen J, Popa-Diaconu D, Hesselstrand R, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis. 2011;70(10):1788-92. doi:10.1136/ard.2010.144360; Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study. Arthritis Rheum. 2005;52(2):592-600. doi:10.1002/art.20787; Simeon CP, Armadans L, Fonollosa V, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford). 2003;42(1):71-5. doi:10.1093/rheumatology/keg033; Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis. 1993;148:1076-82. doi:10.1164/ajrccm/148.4_Pt_1.1076; Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992;47:738-42. doi:10.1136/thx.47.9.738; Pignone A, Matucci-Cerinic M, Lombardi A, et al. High resolution computed tomography in systemic sclerosis. Real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalilities of lung investigation. Clin Rheumatol. 1992;11:465-72. doi:10.1007/BF02283100; Sergiacomi G, De Nardo D, Carpia A, et al. Non-invasive diagnostic and functional evaluation of cardiac and pulmonary involvement in systemic sclerosis. In Vivo. 2004;18:229-35.; Chan TY, Hansell DM, Rubens MB, et al. Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans. Thorax. 1997;52:265-70. doi:10.1136/thx.52.3.265; Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford). 2009;48:40-4. doi:10.1093/rheumatology/kep109; Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004;232:560-7. doi:10.1148/radiol.2322031223; Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33:1789-801.; Assayag D, Kadury S, Hudson M, et al. High resolution computed tomography scoring systems for evaluating interstitial lung disease in systemic sclerosis patients. Rheumatology. 2012;S1:003. doi:10.4172/2161-1149. S1-003; Walsh SLF, Sverzellati N, Devaraj A, et al. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014;69(3):216-22. doi:10.1136/thoraxjnl-2013-203843; Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology. 2013;266(3):936-44. doi:10.1148/radiol.12112516; Sundaram B, Gross BH, Martinez FJ, et al. Accuracy of high-resolution CT in the diagnosis of diff use lung disease: effect of predominance and distribution of findings. AJR Am J Roentgenol. 2008;191(4):1032-9. doi:10.2214/AJR.07.3177; Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49:271-80. doi:10.1093/rheumatology/kep093; Tashkin DP, Elashoff R, Clements PG, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66. doi:10.1056/NEJMoa055120; Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962-9. doi:10.1164/rccm.2111053; Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169(4):977-83. doi:10.2214/ajr.169.4.9308447; Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18(10):1520-8.; Steen VD, Conte C, Owens GR, Medsgar T. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283-9. doi:10.1002/art.1780370903; Zompatori M, Leone MB, Giannotta M, et al. Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography. Radiol Med. 2013;118:1360-72. doi:10.1007/s11547-013-0934-1; Лесняк ВН, Ананьева ЛП, Конева ОА и др. Полуколичественные визуальные методы оценки выраженности интерстициальных поражений легких по данным компьютерной томографии при системной склеродермии. Пульмонология. 2017;27(1):41-50 [Lesnyak VN, Anan'eva LP, Koneva OA, et al. Semi-quantification image methods for assessing severity of scleroderma-associated interstitial lung; disease according to computed tomography data. Pul’monologiya = Russian Pulmonology. 2017;27(1):41-50 (In Russ.)]. doi:10.18093/0869_0189_2017_27_1_41_50.; Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248-54. doi:10.1164/rccm.200706-877OC; Moore O, Goh N, Corte T, et al. Extent of disease on high- resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis – related interstitial lung disease. Rheumatology. 2013;52:155-60. doi:10.1093/rheumatology/kes289; Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-47. doi:10.1002/art.38098; Fischer A, Swigris JJ, Bolster MB, et al. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol 2014;32 Suppl. 86:109-14.; Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relations to extent of disease on computed tomography. Arthritis Rheum. 1997;40:1229-36.; Davas EM, Peppas C, Maragou M, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol. 1999;18(6):455-61. doi:10.1007/s100670050138; White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132(12):947-54. doi:10.7326/0003-4819-132-12-200006200-00004; Vallentini G, Della Rossa A, Bombardier S, et al. European multicentre study of define disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592-8. doi:10.1136/ard.60.6.592; Nichtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM. 2010;103:109-15. doi:10.1093/qjmed/hcp174; Van Laar JM, Farge D, Sont JK, et al. High dose immunoablation and autolougous hematopoetic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis [abstract]. Arthritis Rheum. 2012;64:4167.; Ariani A, Silva M, Seletti V, et al. Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis. Rheumatology. 2017;56:922-7. doi:10.1093/rheumatology/kew480; Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis. 1991;144(3 Pt 1):706-13. doi:10.1164/ajrccm/144.3_Pt_1.706; Lopes AJ, Capone D, Mogami R. Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over fiveyear period. J Bras Pneumol. 2011 Mar-Apr;37(2):144-51. doi:10.1590/S1806-37132011000200003; De Santis M, Bosello SL, Peluso G, et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J. 2012 Jan;6(1):9-17. doi:10.1111/j.1752-699X.2010.00228.x; Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease. Systematic review. Chest. 2014;146(2):422-36. doi:10.1378/chest.13-2626; Khanna D, Brown KK, Klements PJ, et al. Systemic sclerosisassociated interstitial lung diseases – proposed recommendations for future randomized clinical trails. Clin Exp Rheumatol. 2010;28(2 Suppl 58):55-62.; Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011 Oct;63(10):3078-85. doi:10.1002/art.30467; Diot E, Giraudeau B, Diot P, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest. 1999 Sep;116(3):715-20. doi:10.1378/chest.116.3.715; Liu X, Mayes MD, Pedroza C, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken). 2013 Aug;65(8):1375-80. doi:10.1002/acr.21968; McQueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology (Oxford). 2015;54(5):757-67. doi:10.1093/rheumatology/keu463; Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):17-22.; Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up openlabel trial. Arthritis Res Ther. 2010;12(2):54. doi:10.1186/ar2965; Smith V, van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193-7. doi:10.1136/ard.2008.095463; Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52-7. doi:10.3899/jrheum.120778; Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-94. doi:10.1136/annrheumdis-2013-204522; Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353-9. doi:10.1111/resp.12214; Ананьева ЛП, Десинова ОВ, Конева ОА и др. Лечение ритуксимабом интерстициального поражения легких при системной склеродермии. Научно-практическая ревматология. 2013;51(5):514-23 [Ananyeva LP, Desinova OV, Koneva OA, et al. Rituximab treatment for interstitial lung injury in scleroderma systematica. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(5):514-23 (In Russ.)]. doi:10.14412/1995-4484-2013-1542.; Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology. 1990;176:755-9. doi:10.1148/radiology. 176.3.2389033; Remy-Jardin M, Remy J, Wallaert B, et al. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology. 1993;188:499-506. doi:10.1148/radiology. 188.2.8327704; Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2007;134:358-67. doi:10.1378/chest.07-2444; Овсянникова ОБ. Клинико-инструментальная характеристика интерстициального поражения легких при системной склеродермии: Автореф. дис. … канд. мед. наук. Москва; 2017. С. 10-5 [Ovsyannikova OB. Kliniko-instrumental'-naya kharakteristika interstitsial'nogo porazheniya legkikh pri sistemnoi; sklerodermii [Clinical and instrumental characteristics of interstitial lung lesions in systemic scleroderma]: Author's abstract. dis. . cand. med. science. Moscow; 2017. P. 10-5 (In Russ.)].; Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology. 2008;47 Suppl. 5:59-61. doi:10.1093/rheumatology/ken271; Van der Bruggen-Bogaarts BAHA, Broerse JJ, Lammers JWJ, at al. Radiation exposure in standard and high-resolution chest CT scans. Chest. 1995;107:113-5. doi:10.1378/chest.107.1.113; Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-84. doi:10.1056/NEJMra072149; Mayo JR. CT evaluation of diffuse infiltrative lung disease: dose considerations and optimal technique. J Thorac Imaging. 2009;24:252-9. doi:10.1097/RTI.0b013e3181c227b2; Behr J, Furst DE. Pulmonary function tests. Rheumatology. 2008;47 Suppl. 5:65-7. doi:10.1093/rheumatology/ken313

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2623
https://doi.org/10.14412/1995-4484-2018-591-599

Оценка краткосрочной динамики общего числа В-лимфоцитов на фоне лечения ритуксимабом больных системной склеродермией

Πηγή: Научно-практическая ревматология, Vol 0, Iss 0 (2018)

Θεματικοί όροι: системная склеродермия, интерстициальное поражение легких, анти-в-клеточная терапия, в-лимфоциты, ритуксимаб, дозировка, Diseases of the musculoskeletal system, RC925-935

Relation: https://rsp.mediar-press.net/rsp/article/view/2826; https://doaj.org/toc/1995-4484; https://doaj.org/toc/1995-4492; https://doaj.org/article/96ac5ac368d741e3979f43bf1e0f245e

Διαθεσιμότητα: https://doaj.org/article/96ac5ac368d741e3979f43bf1e0f245e

INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS ; Интерстициальное поражение легких, ассоциированное с системной склеродермией (прогрессирующим системным склерозом)

Συγγραφείς: L. P. Ananyeva, Л. П. Ананьева

Πηγή: Rheumatology Science and Practice; Vol 55, No 1 (2017); 87-95 ; Научно-практическая ревматология; Vol 55, No 1 (2017); 87-95 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20171

Θεματικοί όροι: прогноз, interstitial lung disease, multislice spiral computed tomography, forced vital capacity, diffusing capacity of the lung, prognosis, интерстициальное поражение легких, мультиспиральная компьютерная томография, форсированная жизненная емкость легких, диффузионная способность легких

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2343/1548; Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940-4. doi:10.1136/ard.2006.066068; Гусева НГ. Системная склеродермия. В кн.: Сигидин ЯА, Гусева НГ, Иванова ММ. Диффузные болезни соединительной ткани. Москва: Медицина; 2004. С. 341- 57 [Guseva NG. Systemic sclerosis. In: Sigidin YaA, Guseva NG, Ivanova MM. Diffuznye bolezni soedinitel’noi tkani [Diffuse connective tissue disease]. Moscow: Meditsina; 2004. P. 341- 57].; Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557-67. doi:10.1172/JCI31139; Gabrielli E, Avvedimento V, Krieg T. Mechanisms of disease: Scleroderma. N Engl J Med. 2009;360(19):1989-2003. doi:10.1056/NEJMra0806188; Гусева НГ. Системная склеродермия. В кн.: Ревматология. Национальное руководство. Москва; 2008. С. 447-66 [Guseva NG. Systemic sclerosis. In: Revmatologiya. Natsional’noe rukovodstvo [Rheumatology. National guidelines]. Moscow; 2008. P. 447-66].; Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010 Oct;69(10):1809-15. doi:10.1136/ard.2009.114264; Bakst R, Merola JE, Franks AG Jr, Sanchez M. Raynaud's phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008;59:633-53. doi:10.1016/j.jaad.2008.06.004; Алекперов РТ. Синдром Рейно как мультидисциплинарная проблема. Альманах клинической медицины. 2014;35:94-100 [Alekperov RT. Raynaud's syndrome is a multidisciplinary problem. Al’manakh Klinicheskoi Meditsiny. 2014;35:94-100 (In Russ.)].; Afeltra A, Zennaro D, Garzia P, et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol. 2006;35(5):388-94. doi:10.1080/03009740600844381; Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54. doi:10.1164/rccm.200706-877OC. Epub 2008 Mar 27.; Теплова ЛВ, Ананьева ЛП, Лесняк ВН и др. Системная склеродермия с интерстициальным поражением легких: сравнительная клиническая характеристика с больными без поражения легких. Научно-практическая ревматология. 2010;48(3):41-7 [Teplova LV, Ananyeva LP, Lesnyak VN, et al. Scleroderma systematica with interstitial lung lesion: comparative clinical characteristicswith patients without lung lesion. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(3):41-7 (In Russ.)]. doi:10.14412/1995-4484-2010-442; Nichtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM. 2010;103:109-15. doi:10.1093/qjmed/hcp174; Van Laar JM, Farge D, Sont JK, et al. High dose immunoablation and autolougous hematopoetic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis [abstract]. Arthritis Rheum. 2012;64:4167.; Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581-6. doi:10.1164/rccm.2106012; Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Eng J Med. 2006;354:2655-66. doi:10.1056/NEJMoa055120; Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008;134:601-5. doi:10.1378/chest.08-0053; Steen VD, Medsger AT. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437-44. doi:10.1002/1529-0131(200011)43:113.0.CO;2-U; Clements PJ, Roth MD, Elashoff R, et al. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007;66(12):1641-7. doi:10.1136/ard.2007.069518; Nyhtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complication and long-term survival in systemic sclerosis. Arthritis Rheum. 2014;66(6):1625-35. doi:10.1002/art.38390; Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33:1789-801.; Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008;134(2):358-67. doi:10.1378/chest.07-2444; Ананьева ЛП, Теплова ЛВ, Лесняк ВН и др. Клиническая оценка проявлений интерстициальных поражений легких при системной склеродермии по данным компьютерной томографии высокого разрешения. Научно-практическая ревматология. 2011;49(2):30-9 [Anan’eva LP, Teplova LV, Lesnyak VN, et al. Clinical evaluation of the manifestations of interstitial lung injuryin systemic scleroderma from high-resolution computer tomography data. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(2):30-9 (In Russ.)]. doi:10.14412/1995-4484-2011-600; Алекперов РТ, Черемухина ЕО, Ананьева ЛП и др. Одностороннее поражение легких при системной склеродермии (описание случая). Научно-практическая ревматология. 2014;52(4):458-63 [Alekperov RT, Cheremukhina EO, Ananyeva LP, et al. Unilateral lung injury in scleroderma systematica: A case report. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):458-63 (In Russ.)]. doi:10.14412/1995-4484-2014-458-463; Steen VD, Conte C, Owens GR, Medsgar TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283-9. doi:10.1002/art.1780370903; Goldin J, Elashoff R, Kim HJ, et al. Treatment of sclerodermainterstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high- resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009;136(5):1333-40. doi:10.1378/chest.09-0108; Wells AU, Hansell DM, Rubens MB. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthrytis Rheum. 1997;40(7):1229-36.; Greenwald GI, Tashkin DP, Gong H, et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am J Med. 1987;83:83-92. doi:10.1016/0002-9343(87)90501-8; Khanna D, Chi-Hong Tseng, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011;63(10):3078-85. doi:10.1002/art.30467; Assassi S, Sharif R, Lasky RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther. 2010;12:R166. doi:10.1186/ar3125; Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J. 2010 Jan;35(1):112-7. doi:10.1183/09031936.00060209; Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006;55(4):598-602. doi:10.1002/art.22099; Au K, Khanna D, Clements PJ, et al. Current concepts in diseasemodifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep. 2009;11(2):111-9. doi:10.1007/s11926-009-0016-2; Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;8(5):620-8. doi:10.1136/ard.2008.096677; Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016 May 5. pii: S0140-6736(16)00232-4. doi:10.1016/S0140-6736(16)00232-4 [Epub ahead of print].; Ананьева ЛП, Соловьев СК, Бекетова ТВ и др. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495-506 [Ananieva LP, Soloviyov SK, Beketova TV, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):495-506(In Russ.)]. doi:10.14412/1995-4484-2014-495-506

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2343
https://doi.org/10.14412/1995-4484-2017-87-95

СЛУЧАЙ ГРАНУЛЕМАТОЗА С ПОЛИАНГИИТОМ (АНЦА-АССОЦИИРОВАННЫЙ ГРАНУЛЕМАТОЗ) У ДЕВОЧКИ 17 ЛЕТ (СЛУЧАЙ ИЗ ПРАКТИКИ)

Θεματικοί όροι: ИММУНОСУПРЕССИВНАЯ ТЕРАПИЯ, ИНТЕРСТИЦИАЛЬНОЕ ПОРАЖЕНИЕ ЛЕГКИХ, ANCA АССОЦИИРОВАННЫЕ ВАСКУЛИТЫ, immunosuppressive therapy, СИСТЕМНЫЕ, systemic, interstitial lung damage, ANCA-associated vasculitis, 3. Good health

Применение физической легочной реабилитации в составе комплексной терапии у пациентов с интерстициальными поражениями легких различной этиологии

Θεματικοί όροι: interstitial lung disease, coronavirus infection, COVID-19, коронавирусная инфекция, интерстициальное поражение легких, физическая реабилитация, breathing exercises, дыхательная гимнастика, реабилитация, physical rehabilitation, 3. Good health, rehabilitation

CHANGES OF ACTIVITY INDEX AND TOTAL SEVERITY INDEX IN PATIENTS WITH SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE OVER A 5-YEAR FOLLOW-UP PERIOD ; Динамические изменения индекса активности и суммарного индекса тяжести у больных системной склеродермией и интерстициальным поражением легких за 5-летний период наблюдения

Συγγραφείς: O. B. Ovsyannikova, L. P. Ananyeva, V. N. Lesnyak, O. A. Koneva, M. N. Starovoitova, O. V. Desinova, О. Б. Овсянникова, Л. П. Ананьева, В. Н. Лесняк, О. А. Конева, М. Н. Старовойтова, О. В. Десинова

Πηγή: Rheumatology Science and Practice; Vol 54, No 3 (2016); 312-317 ; Научно-практическая ревматология; Vol 54, No 3 (2016); 312-317 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20163

Θεματικοί όροι: суммарный индекс тяжести, interstitial lung disease, activity index, total severity index, интерстициальное поражение легких, индекс атерогенности

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2226/1443; Гусева НГ. Системная склеродермия и псевдосклеродермические синдромы. Москва: Медицина; 1993. 65 c. [Guseva NG. Sistemnaya sklerodermiya i psevdosklerodermicheskie sindromy [Systemic scleroderma and pseudoscleroderma syndromes]. Moscow: Meditsina; 1993. 65 p.].; Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940-4. doi:10.1136/ard.2006.066068; Scussel-Lonzetti L, Loyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002;81:154-67. doi:10.1097/00005792-200203000-00005; Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581-90. doi:10.1002/art.1780230510; Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 1994;149:1583-90. doi:10.1164/ajrccm.149.6.8004317; Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437-44. doi:10.1002/1529-0131(200011)43:113.0.CO;2-U; Rubio-Rivas M, Royo C, Semion CP, et al. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:208-19. doi:10.1016/j.semarthrit.2014.05.010; Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev. 2011 Mar;10(5):248-55. doi:10.1016/j.autrev.2010.09.012; Mouthon L, Bereane A, Brauner M, et al. Pneumopathie infiltrante diffuse de la sclerodermie systemique. Rev Mal Respir. 2007;24:1035-46. doi:10.1016/S0761-8425(07)92767-9; Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283-9. doi:10.1002/art.1780370903; Medsger TA Jr, Silman AJ, Stehen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999;26:1117-67.; Medsger TA, Bombardieri S, Czirjak L, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003;21 Suppl 29:S42-6.; Valentini G, Della Rossa A, Bombardieri S, et al. European multicenter study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of a preliminary activity index. Ann Rheum Dis. 2001;60:592-8. doi:10.1136/ard.60.6.592; Della Rossa A, Valentini G, Bombardieri S, et al. European multicenter study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients of 19 centers. Ann Rheum Dis. 2001;60:585-91. doi:10.1136/ard.60.6.585; Kowal-Bielecka O, Landeve R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rhem Dis. 2009;68(5):620-9. doi:10.1136/ard.2008.096677; Kahaleh MB, Sultany GL, Smith EA, et al. A modified scleroderma skin scoring method. Clin Exp Rheumatol. 1986;4:367-9.; Geirsson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis. 2001;60:1117-22. doi:10.1136/ard.60.12.1117; Lanteri A, Sobanski V, Langlois C, et al. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev. 2014 Sep;13(9):974-80. doi:10.1016/j.autrev.2014.07.003. Epub 2014 Jul 25.; Vanthuyne M, Smith V, de Langhe E, et al. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol. 2012 Nov; 39(11):2127-33. doi:10.3899/jrheum.120283; Гусева НГ, Волков АВ, Старовойтова МН. Особенности клинических проявлений и течения системной склеродермии в зависимости от пола и возраста начала болезни. Терапевтический архив. 2004;(5):7-11 [Guseva NG, Volkov AV, Starovoitova MN. Features of clinical manifestations and course of systemic sclerosis depending on the sex and age of disease onset. Terapevticheskii Arkhiv. 2004;(5):7-11 (In Russ.)].; Reveille JD, Solomon DH, American College of Rheumatology, Ad Hoc Committee on Immunological Testing Guidelines. Evidence-based guidelines for the use of immunologic laboratory tests: anti-centromere, Scl-70 and nucleolar antibodies. Arthritis Care Res. 2003 June; 49(3): 399-412. doi:10.1002/art.11113; Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med. 1997;103:242-8. doi:10.1016/S0002-9343(97)00023-5; Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with progressive systemic sclerosis. Arthritis Rheum. 1988;31:196-203. doi:10.1002/art.1780310207; Jacobsen S, Halberg P, Ullman S, van et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol. 1998;37:39-45. doi:10.1093/rheumatology/37.1.39; Wangkaew S, Euathrongchit J, Wattanawittawas P, et al. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study. Mod Rheumatol. 2016 Jul;26(4):588-93. doi:10.3109/14397595.2015.1115455. Epub 2015 Dec 23.; Старовойтова МН, Ананьева ЛП, Конева ОА и др. Использование международного индекса для оценки активности системной склеродермии. Современная ревматология. 2013;7(1):34-40 [Starovoitova MN, Ananyeva LP, Koneva OA, et al. Use of the international systemic scleroderma activity index. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2013;7(1):34-40 (In Russ.)]. doi:10.14412/1996-7012-2013-2365; Vettori S, Cuomo G, Abignano G, et al. Impact of the European Sclerodema study group activity index on survival of systemic sclerosis patients from a single Italian center. Clin Exp Rheum. 2010;I Systemic Sclerosis World congress Abstr:10.; Budulgan M, Dilek B, Dag SB, et al. Relationship between serum leptin level and disease activity in patients with systemic sclerosis. Clin Rheumatol. 2014 Mar; 33(3):335-9. doi:10.1007/s10067-013-2459-0; Olewicz-Gawlik A, Danczak-Pazdrowska A, Kuznar-Kaminska B, et al. Circulating adipokines and organ involvement in patients with systemic sclerosis. Acta Rheumatol Port. 2015 AprJun;40(2):156-62.; Radic M, Kaliterna DM, Bonacin D, et al. Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis? Rheumatol Int. 2013 Nov;33(11):2943-8. doi:10.1007/s00296-012-2585-z

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2226
https://doi.org/10.14412/1995-4484-2016-312-317

RECURRENT ANCA-ASSOCIATED VASCULITIS AFTER KIDNEY ALLOTRANSPLANTATION ; Рецидив АНЦА-ассоциированного васкулита после аллотрансплантации почки

Συγγραφείς: N. F. Frolova, L. Yu. Artyukhina, E. S. Stolyarevich, Н. Ф. Фролова, Л. Ю. Артюхина, Е. С. Столяревич

Πηγή: Rheumatology Science and Practice; Vol 54, No 1 (2016); 105-107 ; Научно-практическая ревматология; Vol 54, No 1 (2016); 105-107 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20161

Θεματικοί όροι: ритуксимаб, kidney allotransplantation, glomerulonephritis, interstitial lung injury, rituximab, аллотрансплантация почки, гломерулонефрит, интерстициальное поражение легких

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2175/1396; Berden A, Ferrario F, Hagen E, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628-36. doi:10.1681/ASN.2010050477; Ferrario F, Vanzati A, Pagni F. Pathology of ANCA-associated vasculitis. Clin Exp Nephrol. 2013;17(5):652-8. doi:10.1007/s10157-012-0701-8; Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90:19-27. doi:10.1097/MD.0b013e318205a4c6; Бекетова ТВ. Микроскопический полиангиит, ассоциированный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Терапевтический архив. 2015;87(5):33-47 [Beketova TV. Microscopic polyangiitis associated with anti-neutrophil cytoplasmic antibody: clinical features. Terapevticheskii arkhiv. 2015;87(5):33-47 (In Russ.)].; Pagnoux C, Hogan S, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-18. doi:10.1002/art.23800; Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306-9. doi:10.1093/rheumatology/ket445; Moran S, Little M. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol. 2014;26(1):37-41. doi:10.1097/BOR.0000000000000006; Elmedhem A, Adu D, Savage CO. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant. 2003;18(5):1001-4. doi:10.1093/ndt/gfg087; Столяревич ЕС, Томилина НА. Эволюция представлений о причинах поздней дисфункции трансплантированной почки. Вестник трансплантологии и искусственных органов. 2015;17(2):113-5 [Stolyarevich ES, Tomilina NA. The evolution of ideas about the causes of late dysfunction of the transplanted kidney. Vestnik transplantologii i iskusstvennykh organov. 2015;17(2):113-5 (In Russ.)].; Stegeman C, Tervaert J, van Son W, Tegzess A. Necrotizing glomerulonephritis associated with antimyeloperoxidase antibodies in a renal transplant recipient with renal failure of unknown origin. Nephrol Dial Transplant. 1994;9(7):839-42.; Kuross S, Davin T, Kjellstrand CM. Wegener's granulomatosis with severe renal failure: clinical course and results of dialysis and transplantation. Clin Nephrol. 1981;16(4):172-80.; Clarke A, Bitton A, Eappen R, et al. Treatment of Wegener's granulomatosis after renal transplantation: is cyclosporine the preferred treatment? Transplantation. 1990;50(6):1047-51. doi:10.1097/00007890-199012000-00030; Nachman P, Segelmark M, Westman K, et al. Recurrent ANCAassociated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int. 1999;56(4):1544-50. doi:10.1046/j.1523-1755.1999.00666.x; Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 1998;9(7):1258-63.; Gera M, Griffin M, Specks U, et al. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int. 2007;71(12):1296-301. doi:10.1038/sj.ki.5002244; Geetha D, Seo P. Renal transplantation in the ANCA-associated vasculitides. Am J Transplant. 2007;7(12):2657-62. doi:10.1111/j.1600-6143.2007.01988.x; Murakami C, Manoharan P, Carter-Monroe N, Geetha D. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant. Transpl Int. 2013;26(12):1225-31. doi:10.1111/tri.12203

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2175
https://doi.org/10.14412/1995-4484-2016-105-107